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Molecular pathogenesis of natural killer/T-cell lymphomas
Bei Jiang, Ph.D.
University of Nebraska Medical Center, 2016
Supervisor: Wing-Chung (John) Chan, MD and Kai Fu, M.D., Ph.D.
Extranodal natural killer/T-cell lymphomas (NKTCL) are uncommon lymphomas with
poor prognosis. In order to gain a better understanding of the molecular pathogenesis of
NKTCL, we obtained and compared the global gene expression profile, global somatic
mutation profile, and global methylation profile of normal NK cells, malignant NK cell
lines, and NKTCL patient samples. We showed that the JAK-STAT pathway was
constitutively activated in NKTCL through the cooperation between activation of signal
transducer and activator of transcription proteins (STATs) via activating mutations and
inactivation of STAT suppressor protein suppressor of cytokine signaling 6 (SOCS6)
through promoter hypermethylation. Activating STAT3 and STAT5B mutations are
associated with increased phosphorylated protein and a growth advantage to transduced
cell lines or normal NK cells. Growth-promoting activity of the mutants can be partially
inhibited by a JAK1/2 inhibitor or by expressing exogenous SOCS6. Molecular modelling
and surface plasmon resonance measurements of the N642H STAT5B mutant indicate a
marked increase in binding affinity of the phosphotyrosine-Y699 with the mutant protein.
This is associated with the prolonged persistence of the mutant phosphoSTAT5B and
marked increase of binding to target sites. We also showed that Blimp1, a tumor
suppressor gene frequently inactivated in NKTCL by the combination of allelic deletion
and promoter hypermethylation, has an effect on NK cell homeostasis, maturation and
function using a NK-lineage specific Blimp1-knockout mouse model. Blimp1 knockout
mice had a lower percentage of NK cells in peripheral lymphoid sites, such as spleen
and peripheral blood, and higher percentage of NK cells in bone marrow when
compared to wild-type mice. The maturation of NK cells was partially impaired in Blimp1
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knockout mice. However, Blimp1-deficient NK cells proliferated better upon stimulation in
vitro and in vivo, and had a potent cytotoxic ability. Together, these findings suggest
potential pathways for therapeutic targeting in NKTCL patients.
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Chapter I
Introduction

2
NK cell
The lymphocyte is a subtype of white blood cell in a vertebrate’s immune system that
plays an important role in immunosurveillance. Innate lymphoid cells (ILC) are group of
innate immune cells that are derived from the lymphoid lineage but do not respond in an
antigen-specific manner, as they lack somatic rearrangement of immunoglobulin and T
cell receptor genes. There are three types of ILCs characterized based on cytokine
secretion and transcriptional factor expression, NK cells are one of two group 1 ILC
described to date. NK cells can kill pathogen-infected cells or malignant cells by
releasing cytotoxic molecules such as perforin and granzymes. Upon degranulation,
perforin can form pores on the target cell’s plasma membrane. Granzymes then enter
the target cell through the pore and cleave caspase-3 and Bid, which results in apoptosis
(Buzza and Bird, 2006). NK cells can also protect the host by augmenting and recruiting
other immune cells via secretion of cytokines, such as TNFα, TNFβ and IFNγ, and
chemokines such as MIP-1α, MIP-1β and RANTES (Fauriat et al., 2010).
NK cell anatomical localization and maturation
NK cells localize throughout lymphoid and non-lymphoid tissues. In most tissues, NK
cells comprise a small fraction of all lymphocytes (Gregoire et al., 2007). It is believed
that NK cells develop from a common lymphoid progenitor (CLP) in the bone
marrow(Kondo et al., 2001).

However, studies show that NK cells in thymus and

secondary lymphoid organs such as lymph nodes, have distinct phenotypic and
functional features compared to those in the spleen and peripheral blood. Both CD34+
HPCs and downstream NK cell developmental intermediates have been identified in
liver, uterus and mucosa-associated lymphoid tissue (MALT). Taken together, it is
commonly accepted that NK cell developmental intermediates originate in the bone
marrow then traffic to extramedullary tissues such as lymph nodes, liver, spleen and give
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rise to functionally distinct mature NK cell subsets.(Res et al., 1996, Di Santo, 2006).
CLPs can differentiate into NK cell progenitors (NKPs), marked by the expression of
IL2/IL-15 receptor beta chain (IL2RB), also known as CD122 (Di Santo, 2006). IL-15
selectively promotes NK cell differentiation, proliferation and survival (Becknell and
Caligiuri, 2005). The committed NKP then acquires functional receptors in an orderly
fashion as they become functionally mature. In mice, NKPs first acquire NK1.1,
CD94/NKG2A, and NKp46 followed by Ly49 receptors, DX5, and finally CD43 and Mac1 (CD11b)(Kim et al., 2002). In human NK cells, receptors are expressed in the following
order: CD161, CD56, CD94/NKG2A, NKp46, and NKG2D, killer immunoglobulin-like
receptors (KIR) and CD16 (Freud et al., 2006, Perussia et al., 2005). Mature NK cells
can be divided into different subsets based on the expression of surface molecules.
In mice, 4 populations of NK cells with different expression of CD11b and CD27
are present. NK cell differentiation is a 4-stage process following CD11lowCD27low to
CD11lowCD27high to CD11bhighCD27high cells to the most mature CD11bhighCD27high cells
(Chiossone et al., 2009). CD11lowCD27low double negative (DP) NK cells express low
levels of NK maturation receptors and are considered to represent immature NK cells in
various numbers in different lymphoid sites. CD11lowCD27high NK cells are the major NK
–cell compartment in fetal and neonatal mice, whereas they are mainly found in bone
marrow, lymph nodes and liver in the adult. CD11low NK cells have high proliferation
ability compared to CD11bhigh NK cells. CD11bhigh

NK cells are mostly present in

peripheral sites such as peripheral blood, spleen and liver. CD11bhighCD27high NK cells
have the greatest effector function. CD11bhighCD27high cells are also mostly found in
peripheral sites, but these cells have greater restriction by self MHC (Hayakawa and
Smyth, 2006)
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In human, two subsets of NK cells are identified by expression of CD56 and
CD16. CD56high CD16dim NK cells are the major component of the NK cell population in
lymph nodes and tonsil; they secrete large quantities of cytokines upon stimulation, but
they have low cytotoxic capacity. CD56dimCD16high NK cells account for around 90% of
NK cell population in peripheral blood and spleen. They have high cytotoxic capacity but
have relatively lower capacity for cytokine production (Yu et al., 2013). Despite the
differences in NK lineage markers between mouse NK cells and human cells, several
experiments suggest that CD56high CD16dim human NK cells and CD11low mouse NK
cells share similarities in localization (enrichment in lymph nodes), phenotype
(expression of early NK markers such as IL7R and lack of effector markers such as Ly49
and KIR) and better proliferation ability.
NK cell activation
NK cells, as a member of the innate immune system, can recognize and kill transformed
or virus-infected cells. Unlike cytotoxic T cells, which recognize target cells in a MHC-Idependent manner, NK cells can response to cells that lack MHC-I through release from
inhibitory receptors. Further studies show that besides inhibitory receptors, NK cell also
process various activating receptors, and the interplay between inhibitory and activating
receptors result in the proper response of NK cells to its targets.

NK cells express a repertoire of inhibitory receptors that have different structures
and ligands (Long, 2008), and NK cells are heterogeneous in their expression of
inhibitory receptors.The most common inhibitory receptors are belonged to three
families: killer cell immunoglobulin-like receptors (KIRs), leukocyte immunoglobulin-like
receptors (LILRs) and

Ly49. Most KIRs are inhibitory and dominant but some are

activating. They are present in human and nonhuman primates and are the main
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receptor for MHC I molecules (HLA-A, HLA-B, HLA-C). KIRs are not present in mice,
however Ly 49, which also have both activating and inhibitory isoforms, are the
functional homologues of KIRs in mice. LILRs are recently discovered receptors, the
inhibitory receptors are found on NK cells. KIRs and LILRs belong to the immunoglobulin
superfamily which has Ig-like extracellular domains, whereas others, such as Ly49 and
CD94-NKG2A receptors have a C-type lectin—like scaffold. The differences in their
extracellular domains determin their ligand binding specificity. However, regardless the
differences in their extracellular region, all the inhibitory receptors share a common
immunoreceptor tyrosin-based inhibitory motif (ITIM) in their intracellular region. The
inhibitory MHC I receptor interacts with MHC I molecules constitutively expressed on
normal cells and suppress NK cell activation when engaged. Since MHC class I
molecules are the main mechanism by which cells display viral or tumor antigens to
cytotoxic T cells, some intracellular microbes and tumors cells adapt to downregulate
their MHC I molecules on cell surface in order to avoid the killing by T cells. This causes
NK cells losing the inhibitory signal and becoming more prone to activation. This
"missing-self recognition" mechanism allows NK cells to be tolerant to self while able to
kill stressed or infected cells (Yokoyama and Plougastel, 2003)
Unlike T and B cells, instead of having a dominant activation receptor, NK cells
process different activating receptors. There are three major activating receptors in both
human and mouse NK cells: the ITAM-bearing NK receptors such as CD16 (FCGR3A,
which binds to the Fc portion of antibodies and allows NK cells to kill through antibodydependent cellular cytotoxicity [ADCC]), the DAP10-associated NKG2D receptor, and
the CD244 receptor(Moretta et al., 2001). Studies show that none of the activating
receptor, except CD16, can activate NK cell alone. Only when the combination of
several activating receptors transmit a activating signal that counterbalances the
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inhibitory signal from inhibitory receptors, will the NK cell be activated (Lanier, 2008). NK
cell’s effector functions are also dependent on the cytokine microenvironment and
interaction with other cells such as T cells and macrophages. IL-2 and IL15 are potent
activators of human and mouse NK cells and have been used for NK cell culture (Sun et
al., 2009).

γδT cell
Gamma delta T cells (γδ T cells) are a rare subset of T cells with a TCR composed of a
γ chain and a δ chain, in contrast to the mainstream alpha beta T cells (αβ T cells),
which have TCRs that is made up of α and β TCR chains. γδ T cells are considered to
be a bridge between innate and adaptive immunity in that as they express both natural
killer receptors such as NKG2D and γδ T cell receptors (Kong et al., 2009). On one
hand, γδ T cells rearrange TCR genes to produce recombinatorial and junctional
diversity and develop a memory phenotype as other adaptive immunity cells and interact
with T and B cells in the adaptive immune system; on the other hand, they can recognize
targets in a MHC-independent manner and they also have phagocytic and cytotoxic
functions that are used by NK cells or macrophages in the innate immune system (Wu et
al., 2014). Compare to αβ T cells, γδ T cells display more diverse functions. Similar to αβ
T cells, they can provide help for B cells(Vantourout and Hayday, 2013), secrete
cytokines such as IL10, IL17, IFN-γ and TNFα to activate or recruit other cells and kill
malignant cells (Kong et al., 2009). In addition, they can present antigen to αβ T cells as
antigen present cells (APC) (Brandes et al., 2005), and they play a role in maintaining
epidermal integrity by secreting different kinds of growth factors (Schilbach et al., 2000).
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γδ T cells cell anatomical localization and maturation
Both αβ and γδ T cells are developed from double negative (DN) CD3+ T cell precursors
in the thymus. γδ T cells are mainly distributed in the skin and gut mucosa, within a
population of lymphocytes known as intraepithelial lymphocytes (IELs)(Petermann et al.,
2010). In human, there are three major γδ T cell subsets: Vδ1, Vδ2 and Vδ3 T cells. Vδ1
T cells are prominent in the intraepithelial location of mucosal surfaces. They maintain
epithelial tissue integrity during damage, infection, or transformation by producing growth
factors and cytokines. Vδ2 chain pairs almost exclusively with Vγ9 chain to form Vδ2 γ9
T cells. They comprise up to 50-90% of the peripheral γδ T-cell population and can serve
as professional APCs, as they express MHC-II and costimulatory molecules such as
CD80 and CD86 upon activation. Vδ3 T cells comprise only 0.2% of circulating T cells,
but they are more frequent in patients with leukemia and chronic infections. They can
express T cell and NK cell markers such as CD4, CD8, CD56, CD161 and NKG2D.
γδ T cells activation
Some γδ T cells recognize phosphoantigens such as (E)-4-hydroxy-3-methyl-but-2-enyl
diphosphate (HMB-PP), an immediate upstream metabolite of isopentenyl diphosphate
(IPP), in killed microorganisms including bacteria such as Mycobacterium tuberculosis.
Human cells also produce IPP, but in physiologically concentration it is not sufficient to
activate γδ T cells. However, certain tumor cells produce higher concentrations of IPP
and activate γδ T cells. Cell-to-cell interaction with APC is required for the binding of γδ
TCR and phosphoantigens, but antigen processing and MHC molecules are not required
since γδ T cells use their TCR in a pattern recognition manner. Besides TCR signaling,
activation of γδ T cells also requires other costimulatory molecules. Three major
catergories of costimulatory molecules are used by γδ T cells: immunoglobulin (Ig)
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superfamily coreceptors such as CD28, tumor necrosis factor receptor family members
such as CD27 and atypical costimulatory molecules such as NKG2D. NKG2D is an
important stimulatory molecule in other cytotoxic cells such as CD8+ T cells and NK
cells. In γδ T cells, NKG2D can either directly activate γδ T cells, as in NK cells, or act as
a co-receptor to the TCR as in CD8+ T cells. Thus, γδ T cells share features and function
with both NK cells and CD8+ T cells. This phenomenon is also observed in disease
states, as NK/T cell lymphomas are derived from both NK cells and γδ T cells.

Extranodal natural killer/T-cell lymphoma
Extranodal natural killer/T-cell lymphomas (NKTCL) are uncommon lymphomas
comprising about 1-2 % of all non-Hodgkin lymphoma (Vanherberghen et al., 2013). This
disease has a high incidence in Asian and Central and South America. NKTCL is a
group of diseases, caused by clonal proliferation of cytotoxic lymphocytes, with unique
clinicopathologic features marked by a predilection to the nasal and paranasal areas
with extensive necrosis and angioinvasion. Most of NKTCLs originate from NK cells, and
the neoplasm cells are CD2+,CD56+,cCD3e+, CD7+,CD16+/-, cytotoxic granuleassociated protein+, but TCR or immunoglobulin gene rearrangements are absent. A
small fraction of NKTCL is of δT cell origin, and they share very similar clinical and
pathological features with the NK cell derived lymphoma. Lesions most often present as
tumor or destruction in extranodal sites, classically in nasal and paranasal areas but may
also affect the upper respiratory tract, gastrointestinal tract and skin (Aozasa et al.,
2008). NKTCL is an aggressive disease with poor prognosis for extranasal disease.
Localized nasal and paranasal diseases are highly responsive to radiation therapy and
have much better outcome.Traditional CHOP therapy showed little effect on NKTCL,
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whereas

an

L-asparaginase-

containing

SMILE

chemotherapy

regimen

(dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide) shows much
better results (Jaccard et al., 2011). Although progress has been made in combining
modified chemotherapy with radiotherapy and autologous bone marrow transplantation,
many NKTCLs are not cured. Therefore, it is necessary to investigate the pathogenesis
of NKTCL to discover new therapeutic targets.

Pathway alterations observed in NKTCL
NKTCL development is a multifactorial process. The high EBV infection rate and limited
geographic distribution of this disease indicate an important role of EBV infection and
genetic/environmental factors in the pathogenethsis of NKTCL. In addition, genetic
alterations, including the activation of oncogenes and inactivation of tumor suppressor
genes also contribute to NK/T cell malignant transformation. In our laboratory and
others, studies were conducted at different levels aiming to decipher the genetic
alterations in NKTCL. At the chromosome level, genome-wide array-based comparative
genomic hybridization (aCGH) was used to identify chromosomal copy number
abnormalities such as deletion, amplification and fusion associated with NKTCL. At the
DNA level, global somatic mutation profiles are explored commonly by whole-exon
sequencing, whereas epigenetic changes such as DNA methylation can be detected by
DNA methylation assays. At the RNA level, the gene expression profiles (GEP) of
NKTCL were analyzed and compared to those of normal NK cells or other
leukemia/lymphoma by microarray-based methods and more recently by RNAsequencing. However, there is no proteomics study on NKTCL.
Genome-wide profiling studies described above identified several potential
molecular pathways that might play an important role in pathogenesis of NKTCL. Gene
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expression profile studies shown that several pathways such as JAK-STAT,
Angiogenesis, platelet-derived growth factor receptor (PDGFR), NOTCH, WNT, and
NFκB signaling pathways are activated in NKTCL(Huang et al., 2010, Iqbal et al., Ng et
al.). The activation of oncogenic pathways was usually due to activation of oncogens
through amplification or activating mutation and/or inactivation of tumor suppressor
genes by mechanisms like allele deletion, missense/nonsense mutations or DNA
methylation. Some important pathways related to this study are described below.
EBV infection and Lmp1expression
A distinctive feature of NKTCL is the strong association with Epstein–Barr virus infection;
EBV is positive in 100% of NKTCL cases by in situ hybridization(Chiang et al., 1996).
EBV undergoes latency II infection in NK cells, in which they only express a restricted
pattern of viral proteins limiting to EBNA1, LMP1, and LMP2 (Xu et al., 2001). EBNA1 is
required for the maintenance of viral episomes and expressed in all latency phases.
LMP2B can promote cell proliferation and survival. LMP1 is the main transforming
protein of EBV. The N-terminal six-transmembrane domain (6TM) of Lmp1 regulates its
own transcription and degradation through its activation of unfolded protein response
and autophagy. Its C-terminal domain activate several downstream molecules such as
nuclear factor-κB (NF-κB) and activating protein 1 (AP-1) and signal transducer and
activator of transcription (STAT) , leading to NK/T-cell activation and proliferation(Chen,
2012).Thus Lmp1 acts like a constitutively activated tumor necrosis factor receptor
family member, in fact in B cell Lmp1 can substitute for the signaling of CD40(Graham et
al., 2010), another member of TNF family. In vitro study shown that Lmp1 silencing in
EBV+ NK cell line resulted in decreased cell proliferation and survival and a reduction in
cell invasion and migration, suggesting the oncogenic role of Lmp1 in NKTCL(Sun et al.,
2015).
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Activation of JAK-STAT pathway
The JAK/STAT pathway is the principal signaling mechanism for a wide array of
cytokines and growth factors. To simplify the process, JAK activation occurs opon
ligand-mediated receptor dimerization or multimerization which allowed the transphosphoralation of JAKs. The activated JAKs subsequently phosphorylate additional
target including the major substrate STATs. The phosphotyrosine of STATs permits the
dimerization of STATS. The dimerizaed STATs then enter nucleus and binds specific
sequence to activate or repress transcription of target gene.

In addition to those

effectors, there are three major classes of negative regulator: SOCS (suppressor of
cytokine signaling), PIAS(protein inhibitor of activated stats) and PTPs(protein tyrosine
phosphotases). The SOCSs complete a negative feedback loop in the JAK/STAT
circuitry: activated STATs stimulate transcription of the SOCS genes and the resulting
SOCS protein bind phosphorylated JAKs and their receptors to turn off the pathway.
Constitutive activation of STAT3 and STAT5 are known to increase tumor cell
proliferation, survival and invasion(Yu et al., 2009).

Aberrant STAT3 and STAT5B

activation were shown in activated B-cell type Diffuse Large B-cell lymphomas (ABCDLBCL) (Lam et al., 2008) and CD8+ Lymphoblastic Lymphoma (Bessette et al., 2008),
respectively. Recently, activating mutations were identified in STAT3 (Jerez et al., 2012,
Koskela et al.) and STAT5B(Rajala et al.) in NK-LGL and T-LGL cases suggesting an
oncogenic role for these mutations. On the other hand, SOCSs the negative regulator of
JAKs are silenced in different tumors. Promoter methylation mediated silencing of
SOCS1 were shown in hepatocellular carcinoma (Yoshikawa et al., 2001) and multiple
myeloma(Galm et al., 2003) , SOCS3 in lung cancer (He et al., 2003) and in
myeloproliferative disorders(Fourouclas et al., 2008) and SOCS6 in gastric cancer(Lai et
al.). It is possible that accumulation of the oncogenic mutations and/ or silencing of the
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negative regulators in JAK-STAT pathway contribute to the neoplastic transformation of
NK cells.
Loss function of Blimp1
According to our study, 6q21 deletion is a frequent chromosomal abnormality observed
in 44% of NKCL cases. PR domain zinc finger protein 1 (PRDM1) is an important
transcriptional regulator within this deleted region. We later found that PRDM1 was
inactivated

in

NKTCL by

the

combination of

allelic

deletion

and

promoter

hypermethylation. Blimp1 is a transcription suppressor; it binds to its target genes in the
promoter region though zinc-finger motifs, and suppresses transcription by recruiting
proteins such as histonedeacetylase1 and 2, G9a histone methyl transferases that
modified histones to create a more inactive structure. PRDM1, also known as B
lymphocyte-induced maturation protein 1(Blimp1), has various effects on the function
and homeostasis of B cells and T cells(Martins and Calame, 2008). In B cells, Blimp1 is
a master regulator of B cell maturation and immunoglobulin secretion(Savitsky and
Calame, 2006). In T cells, Blimp1 regulate cell proliferation and effector functions50,51. In
activation of Blimp1 was observed in several malignancies. Blimp1 was silenced through
hypermethylation in EBV-positive Burkitt lymphoma(Zhang et al., 2014), and in another
study investigators shown that Blimp1 inactivated by multiple mechanisms, including
homozygous deletions, truncating or missense mutations and transcriptional repression
by constitutively active BCL6, in difuse large B cell lymphoma(DLBCL) (Mandelbaum et
al., 2010). In our previous study, knocking down PRDM1 resulted in a positive selection
of NK cells. Whereas ectopic PRDM1 expression in PRDM1-null NK cell lines resulted in
G2/M cell cycle arrest, increased apoptosis, and a strong negative selection. These
finding, along with the observation that PRDM1 was inactivated in NKTCL, indicated that
PRDM1 is a potential tumor suppressor gene in NKTCL.
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Aim of the dissertation
In order to gain a better understanding of the molecular pathogenesis of NKTCL, we
obtained and compared the global gene expression profile, global somatic mutation
profile, and global methylation profile of normal NK cells, malignant NK cell lines as well
as NKTCL patients, and identified potential tumor suppresser genes and oncogenes.
Our previous GEP study shown JAK-STAT pathway was activated in NKTCL. It is
important to investigate the underlining mechanism as this will give us an insight in
potential therapeutic targets. This dissertation explores the underline mechanism of
constitutive JAK-STAT actication in NKTCL and the effect of JAK-STAT activation on NK
cell behaviors. In addition, this study compares the mutation profile of NKTCL and other
γδ-T derived lymphoma; this will give us a better understanding of the ambiguous
relationship between NK cells and γδ-T. Our previous study shown Blimp1 was
frequently inactivated in NKTCL and in vitro experiments in normal malignant human NK
cells indicated Blimp1 as a tumor suppressor gene in NKTCL. Explore the role of Blimp1
in NK cells in mouse model will give us a better understanding as how Blimp1 affects NK
cells in vivo and whether Blimp1 deletion alone or combine with other oncogenic
alternations can lead to malignancies development in vivo.
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Group

Group 1

Cell

Mediators

type

produced

NK cell

IFNγ,

ILCs

Group 2

Perforin,

Immunity to virus and intracellular
pathologens

granzymes

Tumor surveillance

ILC1

IFNγ

Inflammation?

ILC2

IL5,IL9,IL13

Immunity to helminthes

amphiregulin

Wound healing

IL17,IL22,

Lymphoid tissue development

lymphotoxin

Intestinal homeostasis

ILC

Group 3

Function

LTi cell

ILCs

Immunity to extracellular bacteria

Ncr+

IL22

ILC3

Ncr-ILC3

Homeostasis of epithelia
Immunity to extracellular bacteria

IL17, IFNγ

Immunity to extracellular bacteria

15

Table 1-1: Summary of innate lymphoid cell subsets, mediators production and
functions

ILCs are further divided into three groups: group 1 ILCs, group 2 ILCs and group 3 ILCs,
based on their ability to produce type 1, type 2 and TH17 cell-associated cytokines,
respectively. LTi: Lymphoid tissue inducer cell
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Chapter II

Material and method
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Patient samples and cell lines
The phenotypic characteristics of all NKTCL, δγ-PTCL and EATL type II cases (n=94),
NK- and δγ T-cell lines (n= 9) used in this study are summarized in Table 2-1 and Table
2-2. Culture conditions of NK and γδ-T cell lines were as described previously(Iqbal et
al., 2009, Nagata et al., 2001). The DHL16 cell line was cultured in RPMI-1640 (GibcoInvitrogen) including 10% FBS; penicillin G (100 units/mL) and streptomycin (100 μg/mL)
at 37 °C in 5% CO2.
DNA and RNA extraction
Extraction and purification of DNA and RNA from tumor cases were performed
simultaneously using AllPrep DNA/RNA Mini Kit (Qiagen Inc., Valencia, CA) or ALLPrep
DNA/RNA FFPE Kit (Qiagen Inc). Genomic DNA was isolated from NK or γδ T-cell lines
using DNeasy Blood and Tissue Kit (Qiagen Inc.).
Whole transcriptome sequencing and data analysis
RNA-sequencing was performed on resting NK cells, NK-cells activated by IL2 or by
K562-Clone9-mb21, 17 NKTCL cases and 3 NK-cell lines. Briefly, 100-bp paired-end
libraries were prepared with the TrueSeq RNA preparation kit (Illumina Inc., San Diego,
CA), and high-throughput sequencing was performed at the UNMC Next Generation
Sequencing Core facility and Tufts University (TUCF) Genomics Core Facility using
Illumina Genome Analyzer IIX or HiSeq 2000 Sequencing systems. FASTQC reports
were evaluated for each sample to evaluate the quality of basic statistics. Two different
pipelines were used to generate the SNVs.

The main pipeline used for SNV detection

was described previously (Schmitz et al., 2012) with the following addition. In addition to
the NCBI SNP database (dbSNP) and 1000 Genomes project (Abecasis et al., 2012),
three normal NK samples were used to filter out the SNPs. The presence of the SNVs
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was evaluated by visualizing the SNVs using Integrative Genomics Viewer software
(IGV) (http://www.broadinstitute.org/igv). Finally, the Cosmic release v69
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) was used to annotate the
variants observed in previous studies. The secondary pipeline used for SNV detection is
as follows: The read were aligned to the human reference genome (NCBI GRCh37)
using the BWA aligner(Li and Durbin, 2009) with paired-end (sample) mode and with
default options. After merging BAM files, PCR duplications were also removed. Then,
GATK tool (DePristo et al., 2011) was used to realign indel-containing reads to the
reference genome. After realignment, GATK UnifiedGenotyper was used to generate
SNP and indel callsets for 24 (21 malignant and 3 normal NK samples) RNA-Seq
samples, using a merged BAM file including all 24 datasets with specific IDs. Variant
Quality Score Recalibration filter was applied using the GATK resource bundle 1.2 to
help minimize false positives. Then, ANNOVAR tool(Wang et al., 2010), version 201302-11, was used to annotate the detected SNPs and indels. For gene and filter
annotation, the April 2012 version of the annotation database (hg191000g2012apr) and
dbSNP version 137 was used. For comparison against the 1000 Genomes Project, the
data 1000g2012apr was used. Lastly, the SNVs present in three normal NK samples
were filtered out. The basic statistics of RNA-Seq are shown in Table 2-2. Furthermore,
the number of SNVs and their annotations identified by the primary RNA-Seq pipeline for
17 NKTCL cases are shown in Fig. 2-1. The RNA-sequencing data will be deposited into
dbGaP (http://www.ncbi.nlm.nih.gov/gap/) database.
Whole exome-sequencing and data analysis
Trueseq DNA library kit (FC-121-2001, Illumina) was used to prepare libraries of a
NKTCL case DNA and DNA from the peripheral blood of the same patient. Rapid 100-bp
paired-end sequencing was performed with Hiseq2500 (Illumina) at the UNMC Next
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Generation Sequencing Core facility. Raw sequencing reads were mapped to the
human reference genome hg19 using BWA. GATK was used for local realignment and
base quality recalibration. Picard (http://picard.sourceforge.net) was used to mark
duplicates. VarScan(Koboldt et al., 2009) called variants for paired NKTCL and the
corresponding normal sample. In this study, only STAT3 and STAT5B mutation status
was evaluated; the whole sequencing profile will be reported later.
Whole genome amplification
Whole genome amplification (WGA) of the NKTCL (n=20) or γδ-PTCL (n=4) and KAI3
cell line was performed using the Repli-g kit (Qiagen Inc., Valencia, CA). 50 ng of tissue
material was used as a template for amplification. The sensitivity of mutation detection
was evaluated by applying Sanger sequencing on the G to A mutation detected in the
intron4/exon5 splice junction of PRDM1 detected previously (Fig. 2-2A)(Iqbal et al.,
2009). Uniform linear amplification of genomic DNA from each NK sample was tested
with PCR, which generated ~ 3 kb amplicons using KAI3 cell line or NKTCL cases (Fig.
2-2B,C).In addition, WGA DNA from NKTCL cases was run on TAE-agarose gels, which
showed that WGA DNA contains large fragments (>10kb) (Fig. 2-2D).
Compilation of the list of JAK/STAT pathway genes
The list of genes in the JAK/STAT pathway was compiled using the following resources:
1) The genes screened in NK or T-LGL cases in a recent report (Jerez et. al. Blood
2012).2) The JAK-STAT pathway genes defined in Ingeniuty pathway analysis (IPA)
program Ingenuity Systems [http:// www.ingeniuty.com], 3) JAK/STAT pathway genes
shown in Cell Signaling Technology website (http://www.cellsignal.com/pathways/jakstat.jsp). 4) The genes shown to play a role in JAK-STAT pathway based on the
literature.
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Mutation validation by Sanger sequencing
Sanger sequencing was performed on DNA from cryopreserved or FFPE tissues, or
cDNA if only RNA was available. Sequencing was focused on the SH2 domain of STAT3
and STAT5B and the previously reported mutation hotspots for JAK3. The genomic
DNA sequences around the JAK3 A572V, A573V and V722I SNVs was obtained using
UCSC (http: //genome. ucsc. edu/) genome browser. PCR primers covering SNVs were
designed with the PrimerQuest software (IDT DNA technologies, Coralville, IA). The
primers were optimized with gradient PCR, and the forward and reverse primers used for
PCR amplification of WGA or FFPE gDNA or cDNA samples were used for Sanger
sequencing. Analysis of the sequences was performed using Vector NTI 10.3.0
(Invitrogen, Carlsbad, CA, USA) and Sequence Scanner Software v1.0 (Applied
Biosystems Inc.).
Promoter methylation analysis of SOCS6
Methylation specific cut counting (MSCC) procedure was employed to determine the
methylation level of SOCS6 as described earlier (Ball et al., 2009) in NKTCL cases (n=
12) and malignant NK cell lines (n=2). We specifically concentrated on the HpaII sites in
the promoter of SOCS6 (+/- 1 kb of TSS) whereas the complete methylation profile by
MSCC will be published later. The library preparation and high throughput sequencing
was performed at the epigenetic core facility by Illumina Genome Analyzer II X. R
program scripts (http://www.R-project.org) were used to identify the average promoter
MSCC cut count data. To determine the significance of change in count data, an
analysis for fit based on the Poisson distribution at the p=0.05 level was employed.
Based on this analysis, a significant change was determined to be a four-fold or greater
difference between two samples. 48h IL2 activated NK-cells were used as the standard
to evaluate promoter methylation.
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NK-cell isolation and activation for RNA-Seq
Primary human NK cells were isolated from peripheral blood lymphocytes (PBL) using a
human NK-cell isolation kit (Miltenyi Biotec, Auburn, CA) as described
previously(Meinhardt et al., 2012). The purity of NK cells was evaluated by CD56-APC
and CD3-PE double staining, and samples with >95% CD56+CD3- cells were used for
RNA-Seq. Resting NK cells were cultured in the presence of 100 IU of IL2 for 48h to
obtain activated NK cells. Higher levels of NK-cell activation were achieved by
coculturing freshly isolated PBLs with engineered K562 cells, K562-Clone9-mb21, as
described in detail before(Somanchi et al., 2011, Kucuk et al., 2013).
q-RT-PCR
Real-time PCR was performed using DyNAmo HS SYBR Green qPCR Kit (Thermo
Scientific Inc) with CFX Connect (Bio-Rad, Hercules, CA) real time thermocycler. Melting
curve analysis was performed to ensure amplification specificity. The ΔΔCt method was
used to calculate the relative mRNA expression level. Human RPL13A and mouse eEF2
were used for normalization of gene expression in human and mouse samples
respectively.
STAT3 shRNA transfection in 293T cells
The STAT3 shRNA was transfected into 293T cells as follows: 150,000 cells were
seeded in 2 ml using 6-well plates in triplicate 24 h before transfection. 3 µg of PLVTH or
PLVTH-S3S (STAT3 shRNA)(Piva et al., 2010) was transfected into 293T cells using
Turbofect (Thermo Scientific,Waltham, MA) according to the manufacturer’s
recommendations. 51 h post-transfection, cells were harvested for q-RT-PCR.
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Western Blot
Western blot was performed as described previously with the following modifications
(Iqbal et al., 2009). RIPA buffer supplemented with a protease inhibitor cocktail (Sigma
Aldrich, St Louis, MO) and phosphatase inhibitor cocktails 2 and 3 (Sigma Aldrich, St
Louis, MO) was used to prepare the whole cell lysate. 20 µg protein/sample was used
for Western blot. BSA (Sigma-Aldrich, St Louis, MO) was used instead of non-fat dry
milk during blocking. The primary antibodies used for Western blotting are as follows:
STAT3 (Cell Signaling, Danvers, MA), STAT5 (3H7) Rabbit mAb #9358 (Cell Signaling
Inc.,Danvers, MA) ,phospho-STAT5 D47E7 Rabbit mAb # 4322 (Cell Signaling),
phospho-STAT3 (Cell Signaling, Danvers, MA) and α-Tubulin (Sigma-Aldrich).
STAT3 shRNA expression in NK-cell lines
The lentiviral construct used for STAT3 knock-down was described previously (Piva et
al., 2010). Lentiviral transduction of NK-cell lines or DHL16 was performed following the
protocol used for retroviral transduction(Kucuk et al., 2013) with the following
modifications: 4 µg PLVTH or PLVTH-S3S was cotransfected with 2 µg of PMD2G and 2
µg psPAX2 packaging constructs into the 293T cell line to generate lentiviral particles.
Transduction was performed once rather than twice. Transduction efficiency was
determined with fluorescence-activated cell sorting (FACS) 3 days post-transduction.
Generation and expression of the STAT3 or STAT5B mutant constructs
Wild type (WT) STAT5B was PCR-cloned with the high-fidelity PfuUltra II Fusion HS
DNA Polymerase (Agilent Technologies, Palo Alto, CA) using NK92 cell line cDNA as
the template and then cloned into the multiple cloning site (MCS) of the pMIG expression
vector using NotI and SalI restriction sites. Similarly, WT STAT3 was PCR-cloned into
pMIG from KAI3 cell line cDNA using NotI and SalI sites. Diagnostic mapping and full
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insert sequencing was performed. These WT STAT3 or STAT5B constructs were used
as templates for site-directed mutagenesis to generate the STAT3 or STAT5B mutants
used for functional studies as described below apart from the STAT3-Y640F-pMIG
construct, which was PCR-cloned with PfuUltra II Fusion HS DNA Polymerase using the
cDNA from NKYS cells, which have the STAT3 Y640F mutation.
STAT3 or STAT5B SNVs observed in NKTCL, γδ-PTCL or EATL type II samples (patient
samples or cell lines) were generated using the Quick-Change Site-Directed
Mutagenesis Kit (Agilent technologies, Santa Clara, CA) according to the manufacturer’s
instructions using WT STAT3 or STAT5B-pMIG vectors. Diagnostic restriction mapping
and full sequencing of the inserts were performed to ensure the presence of introduced
mutation and absence of another SNV. The primers used for site-directed mutagenesis
(SDM) are as follows:
STAT3-S614R-SDM-F: GAAAGCAGCAAAGAAGGACGCGTCACTTTCACTTGG
STAT3-S614R-SDM-R: GTGACGCCTCCTTCTTTGCGGCTTTCACTGAATCTT
STAT3-G618R-SDM-F: GAAAGCAGCAAAGAAGGACGCGTCACTTTCACTTGG
STAT3-G618R-SDM-R: CCAAGTGAAAGTGACGCGTCCTTCTTTGCTGCTTTC-3
STAT3- D661Y-SDM-F: TGGGCTATAAGATCATGTATGCTACCAATATCCTGG
STAT3- D661Y-SDM-R: CCAGGATATTGGTAGCATACATGATCTTATAGCCCA
STAT3- A702T-SDM-F: AGCTGACCCAGGTAGCACTGCCCCATACCTGAAG
STAT3- A702T-SDM-R: CTTCAGGTATGGGGCAGTGCTACCTGGGTCAGCT
STAT5B-E579K-SDM-F: GGTTTGACGGTGTGATGAAAGTGTTAAAAAAACATC
STAT5B-E579K-SDM-R: GATGTTTTTTTAACACTTTCATCACACCGTCAAACC
STAT5B-N642H-SDM-F: GGAAAGAATGTTTTGGCATCTGATGCCTTTTACC
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STAT5B-N642H-SDM-R: GGTAAAAGGCATCAGATGCCAAAACATTCTTTCC
STAT5B-Y665F-SDM-F: GCTTGGGAGACTTGAATTTCCTTATCTACGTGTTTC
STAT5B- Y665F-SDM-R: GAAACACGTAGATAAGGAAATTCAAGTCTCCCAAGC
STAT5B-I704L-SDM-F: GGATACGTGAAGCCACAGCTCAAGCAAGTGGTCCCTG
STAT5B-I704L-SDM-R: CAGGGACCACTTGCTTGAGCTGTGGCTTCACGTATCC
Retroviral transduction of NK-cell lines was performed as previously described(Kucuk et
al., 2011) with the following modifications: 4 μg of pMIG or pMIG vectors expressing WT
or mutated STAT3/STAT5B gene was cotransfected with 4 μg of the packaging
construct PCL-Ampho into the 293T cell line. A single transduction was performed.
Transduction efficiency was determined with flow cytometry on GFP+ cells 2-4 days
post-transduction. KAI3 cells were cultured in the presence of 20% FBS to increase
transduction efficiency.
SOCS6 cloning and expression in NK-cell lines
The SOCS6 coding sequence (NCBI accession number: NM_004232.3) was PCRamplified with the high-fidelity PfuUltra II Fusion HS DNA Polymerase (Agilent
Technologies, Palo Alto, CA) from 48h IL2 activated human NK cell cDNA and cloned
into the pMIG expression plasmid upstream of the internal ribosomal entry site using
NotI and SalI sites. The construct was validated by diagnostic restriction mapping and
Sanger sequencing of the inserts. Retroviral transduction of NK-cell lines was performed
as previously described with the following modifications: 4 µg of pMIG or pMIG-SOCS6
vector was cotransfected with 4 µg of the packaging construct PCL-Ampho into the 293T
cell line. Single transduction was performed. Transduction efficiency was determined
with flow cytometry on GFP positive cells 2-4 days post-transduction. YT cells were
cultured in the presence of IL2 during transduction to increase transduction efficiency.
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Conditioning primary human NK cells for retroviral transduction
Primary human NK cells were expanded using a special ex vivo system that involves
coculturing primary human NK cells with an engineered NK-cell target, K562-Cl9-mb21,
which activates and induces proliferation of NK cells robustly as described before(Kucuk
et al., 2013, Kucuk et al., 2011). The expansion procedure is briefly as follows: First,
primary human NK cells were isolated by negative selection using EasySepTM Human
NK cell enrichment kit (Stemcell technologies,Vancouver ,Canada). Then, primary NK
cells were admixed in a 1:2 ratio with 100 Gr irradiated K562-Cl9-mb21cells, which
express CD86, 4-1BBL and mIL21 on their surface, and cultured in NK-cell expansion
medium (NKEM) (Somanchi et al., 2011). Cells were spun down at 400 g for 5 min, and
the culture medium was renewed every three days with fresh culture medium, keeping
the cell density at 250,000 cells/ml after every subculture. 9 days after coculture started,
cells were immunostained with CD56-PE (Biolegend, San Diego, CA) and CD3-FITC
(Biolegend) antibodies to determine the NK-cell purity by FACS. On the same day purity
was determined, primary NK cells were transduced with WT or mutant STAT5B retroviral
constructs.
Determination of positive/negative selection of transduced cells using FACS
STAT3 shRNA or STAT3/STAT5B mutant transduced NK cell lines were tracked by
quantification of the GFP+ cells using flow cytometry after transduction to determine
negative or positive selection of cells, respectively, because GFP was used as the
marker of transduction. The following flow cytometers were used for determination of
GFP+ cells: FACS Calibure (BD Biosciences), BD LSRFortessa (BD Biosciences) and
Gallious (Beckman Coulter Inc.) Autofluorescent cells, which emit both green and
orange, represent false positive, untransduced cells, were filtered out through proper
gating. During quantification of GFP+ cells in transduced primary NK cells, dead cells
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were labeled and filtered out by staining the cells with 0.5ug/ml DAPI (Biolegend, cat.no:
422801) for 10 min before flow cytometry.
ChIP-q-PCR
10 million cells isolated from GFP-sorted, empty vector, STAT5B-WT or N642H-mutant
transduced KAI3 cells were used for chromatin immunoprecipitation using ChIP-IT
Express Enzymatic (Active Motif, Carlsbad, CA) following the manufacturer’s
recommendations.The procedure is briefy as follows: The enzymatic digestion time was
optimized as 10 min based on the TAE-agarose gel image. 10*106 cells /sample were
fixed with 1% formaldehyde. After enzymatic fragmentation, STAT5 (3H7) Rabbit mAb
#9358 (Cell Signaling Inc.,Danvers, MA) and rabbit anti-IgG Control (Abcam Inc.,
Cambridge, MA) antibodies were used side-by-side for immunoprecipitations. 20 µg of
chromatin/reaction was immunoprecipitated using dilutions of STAT5 or IgG antibody
based on manufacturers’ recommendations. After elution of DNA , reversal of DNA
crosslinks, and proteinase K treatment, q-PCR was performed using 2 µl of gDNA in
replicate. STAT5 immunoprecipated DNA levels were normalized to the levels of IgG
immunoprecipitated DNA for each sample. STAT5 binding sites reported before for
IL2Ra(Kanai et al., 2014), BCL2(Li et al., 2010),BCL-XL(Kanai et al., 2014), HIF2α(Fatrai
et al., 2011) and MIR155HG(Kopp et al., 2013) were evaluated. The sequences of
ChIP-q-PCR primers used in this study are as follows:
IL2Rα-ChIP-q-PCR-F: AAAACCAATTTCTTGGGATGG-3
IL2Rα-ChIP-q-PCR-R: AGGGGAAATTCCGTTGAGTT
BCL2 ChIP-q-PCR-F: ACTTTACATTTCTGTTGTGTTTACAGC
BCL2 ChIP-q-PCR-R: ATTCATACATATGCACACGCACA
BCL-XL ChIP-q-PCR F: AATTCAGCTGCCAGCCTCT
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BCL-XL ChIP-q-PCR R: CAACCGCTTCCTTTTCTGAG
HIF2α (EPAS1) ChIP-q-PCR F: CAGTGTCCTGAGACTGTATGHIF2α (EPAS1) ChIP-q-PCR R: CTGTCAGACCCGAAAAGA
AZD1480 treatment of mutant STAT3 or STAT5B transduced KAI3 cells
25,000 KAI3 cells were seeded in 2 ml inside 24-well plates in replicates or triplicates
and treated with 0, 0.5 µM, 1 µM or 2 µM of AZD1480 for 72 h. 72 h post-treatment, the
total viable cell number in each well was quantified using a Vi-cell XR Cell Viability
Analyzer (Beckman Coulter Inc.) according to the manufacturer’s instructions. Total cell
number in each treated sample was normalized to that of the untreated control cells.
Three-dimensional structural modeling of the STAT5B-N642H mutant
The STAT5B structure was modeled on the available STAT5A structure (PDB ID: 1Y1U)
using the program MODELLER(Sali and Blundell, 1993). There was little difference in
the SH2 domains as these two proteins have extremely similar primary sequences.
Then, the modeled STAT5B SH2 domain was compared to other proteins containing
SH2 domains that had been co-crystallized with peptides (v-SRC, GRB2, SH2B, NCK2)
which showed the site of the N642H was directly located in the key binding pocket of the
phosphorylated tyrosine. Phosphorylated self-peptide (STAT5B: VDG-PTR-VKPQ) was
docked into the SH2 domain of WT-STAT5B or N642H-STAT5B, respectively. Proteinprotein docking was done with the FFT-based docking tool ClusPro(Comeau et al.,
2004) on a dedicated server. Key binding residues (STAT5B: R618, S620, N621, K600,
N642) were specified based on previous peptide-SH2 domains co-crystallized structures
(PDB ID: 2HDX, 1SHA, 2CIA, 1TZE). The best docking results were selected based on
an electrostatically favored scoring function. ClusPro docking server first clustered 1000
ligand positions with the lowest energy score according to the 9 angstrom C-alpha
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RMSD radius and then ranked the best model. With the energy-minimized proteinpeptide docked model, the binding energy of the complex was calculated with MolDock
(Thomsen and Christensen, 2006).
Wild-type and N642H mutant STAT5B cloning, expression and purification for
surface plasmon resonance (SPR)
For surface plasmon resonance, wild-type (WT) and N642H-mutant STAT5B [residues
between 128aa-717aa, NM_012448] was PCR-cloned into the SMT3-pET28b+ plasmid
using the BamHI and XhoI cloning sites. BclI instead of BamHI restriction site was used
in the forward primer to prevent digestion of STAT5B due to the presence of an internal
BamHI site. A TGA stop codon was included in the reverse primer so that C-term His
was not expressed. High-fidelity PfuUltra II Fusion HS DNA Polymerase (Agilent
Technologies, Palo Alto, CA) was used to amplify STAT5B insert from STAT5B-WTpMIG vector. Diagnostic mapping and Sanger sequencing of the inserts and the
integration sites were performed to check the quality of the clones.
WT and mutant STAT5B expression was performed as follows: Plasmid DNA was
transformed into BL21 (DE3) Codon Plus RIL competent cells (Agilent Technologies)
and plated on LB agar plates with chloramphenicol (Cam) and kanamycin (Kan). Single
colonies were selected and grown in LB media with Cam and Kan overnight at 37 °C. 6
X 6 mL of overnight culture was used to inoculate 6 X 1L LB media with Kan and Cam.
Cultures were grown at 37 °C to an optical density of 0.6, then flasks were moved to a
pre-cooled shaker at 18 °C. Cultures were grown at 18 °C until they reached an optical
density between 0.9-1.1. Protein expression was induced with a final concentration of
500 µM IPTG, and cells were allowed to grow 16-20 hrs at 18 °C with continued shaking.
Cells were harvested by centrifugation, resuspended in PBS and frozen at -20 °C until
purification.
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His6-SMT fusions of both WT and N642 mutant STAT5B were purified as previously
published (Donaldson et al., 2013). Briefly, cells were thawed and lysed by French
pressure cell with DNase I and PMSF. Lysates were clarified by centrifugation and
filtration. Lysates were applied to Ni-NTA (Thermo Scientific HisPur) and washed with a
PBS/ imidazole gradient. Eluted protein was dialyzed overnight at 4 °C into PBS in the
presence of His6-ULP1 enzyme with 1 mM DTT. The dialyzed protein was incubated
with Ni-NTA beads prior to concentration to remove uncleaved material, His6-SMT and
His6-ULP1. The unbound material was then loaded onto the preparative grade superdex
G200 gel filtration column (GE lifesciences) and exchanged into 50 mM Tris pH 8.0, 100
mM NaCl, 1 mM EDTA, and 1 mM DTT on column. The peak eluting at ~190 mL was
concentrated, aliquotted into small volumes, and stored at -80 °C.
Surface plasmon resonance binding assay
SPR studies were carried out with the GE Lifesciences Biacore T100 instrument at 25
°C. STAT5B WT and N642H variant ligands were thawed and extensively dialyzed into
HBS-N buffer (GE lifesciences). 50 µg/mL samples of protein were made by diluting the
dialyzed stock samples into acetate pH 5.0 buffer immediately before immobilization.
Both STAT5B proteins were coupled using EDC/NHS amine coupling chemistry with
final immobilization levels of 5345.6 RU for WT and 5433.9 RU for N642H variant.
Reference channels received a blank amine coupling protocol. The analyte,
phosphopeptide (KAVDG (p) YVKPQI) (Anaspec, Fremont, CA) was prepared by
dissolution in water and extensive dialysis into water. The peptide stock solution was
stored at 4 °C prior to analysis. 2-fold dilutions of the phosphopeptide stock were
prepared in HBS-EP+ (GE lifesciences) ranging from 100 µM to 0.78 µM immediately
prior to analysis. Peptide samples were flowed over the immobilized ligand at a rate of
30 µL/min with each concentration being run in duplicate. HBS-EP+ was used both as
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running and regeneration buffer. KD values were calculated using BiaEvaluation software
(Biacore AS, Uppsala, Sweeden) by fitting the binding isotherms to a 1:1 Langmuir
model.
STAT5B Triple flag tag vector construction
A triple flag tag sequence was fused to C terminal of wild-type and mutant STAT5B and
inserted into PMIG vector. For regulated STAT5B expression, triple flag STAT5
sequence were inserted into pBMN-DHFR-YFP vector so that the sequence was fused
with DHFR on its C terminal. The triple flag tag sequence used in the experiment is:GAC
TAC AAGGAC CACGAC GGTGAC TAC AAGGAC CACGACATCGACTAC
AAGGACGACGACGACAAGTGA (D Y K D H D G D Y K D H D I D Y K D D D D K Stop)
CHIP-Seq assay
10 million cells isolated from GFP-sorted, empty PMIG vector, STAT5B-WT-3xFlag or
STAT5B-N642H-3xFlag-PMIG transduced KAI3 cells were used for chromatin
immunoprecipitation using ChIP-IT Express Enzymatic (Active Motif, Carlsbad, CA)
following the manufacturer’s recommendations. The procedure is briefy as follows: The
enzymatic digestion time was optimized as 10 min based on the TAE-agarose gel
image. 10*106 cells /sample were fixed with 1% formaldehyde. After enzymatic
fragmentation, Anti-Flag mAb () #9358 (Cell Signaling Inc.,Danvers, MA) and rabbit
anti-IgG Control (Abcam Inc., Cambridge, MA) antibodies were used side-by-side for
immunoprecipitations. 20 µg of chromatin/reaction was immunoprecipitated using
dilutions of STAT5 or IgG antibody based on manufacturers’ recommendations. After
elution of DNA, reversal of DNA crosslinks, and proteinase K treatment, q-PCR was
performed using 2 µl of gDNA in replicate. STAT5 immunoprecipated DNA levels were
normalized to the levels of IgG immunoprecipitated DNA for each sample. STAT5
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binding sites reported before for KAI3 cells were transduced with empty PMIG vector,
wild-type STAT55-Flag-PMIG and STAT5B-N642H-Flag-PMIG. GFP positive cells were
sorted 4 days after transduction. 1 x 10 7 cells were used for Immune-precipitation.
Donor vector and sgRNA generation for STAT5B mouse
The loxp flanked wild type STAT5B- STAT5B N642H construct was inserted into
Bluescript vector by Gibson assembly. Primers with 20bp overhang were used to amplify
each sequence. 5’ homology arm, mouse wild type STAT5B exon16, 3’ homology arm
were amplified from mouse genome. Huamn N642H STAT5B exon 16 was amplified
from patient sample. Sequence containing two paired of loxP sites were amplified from
vector MSCV- FLIPi-P2G-Thy1.1-PTEN vector (Addgene). Primers for Gibson assembly
are as follows:
STAT5BMM5'FLANK-F:,CCGGGCTGCAGGAATTCGATGGACGGAATTACACTTTCTG
STAT5BMM5'FLANK-R:
GTTATAGACTAAGGAAGGAATGGTCATTCTTAGGTGGCAATGTTAGCAGCAACACC
TGCCATTAATTAGAG
5'2XLOXP-SPACER-F:
TTCCTTCCTTAGTCTATAACTTCGTATAGGATACCTTATACGAAGTTATGGTGAACC
GCATCGAGCTGAAG
5'2XLOXP-SPACER-R:
GTAAACCTTGATAACTTCGTATAATGTGTACTATACGAAGTTATCACGAACTCCAGC
AGGACCATGTG
STAT5BHU-EX16-FLANKS-F: ACGAAGTTATCAAGGTTTACATCTGCCC
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STAT5BHU-EX16-FLANKS-R:
GGACTTCTTGGGTTATTTTTAAATGGAGATTTCTATTG STAT5BMU-EX16-FLANK-F:
AAAAATAACCCAAGAAGTCCCCGTTGGC
STAT5BMU-EX16-FLANK-R : CCCAGCCATCGCCCTGGGTATTGCCTGA
3'2XLOXP-F: TACCCAGGGCGATGGCTGGGTTCATGGTG
3'2XLOXP-F:
ACGAATTTGTGTATTTCCTAAGAATTTTACGACAATATGATAAGCTTGGCTGCAGG
STAT5BMU3'FLANK-F:
TAGGAAATACACAAATTCGTGAGAAAGAAAGACTTCACACACATCTTGATGCTGGCT
CTG
STAT5BMU3'FLANK-R: ACGGTATCGATAAGCTTGATGGATACTCTAGGAAACTCAG
sgRNA sequence was cloned into T7-promoter containing pUC57-sgRNA
expression vector using Bsal sites as described previously(Shen et al., 2014). Vector
were linearized DraI and in vitro–transcribed using the MEGAshortscript Kit (Ambion,
AM1354). sgRNAs were purified by MEGAclear Kit (Ambion, AM1908). To test sgNRA
efficiency, sgRNA sequence were cloned into CAS9 expressing vector pSpCas9 (BB)2A-GFP. 3T3 cells were transfected with sgRNA containing pSpCas9(BB)-2A-GFP
plasmid, DNA were isolated 2 days posttransfection and Cas9 mediated edition was
tested with SURVEYOR assay (Invitrogen) (Cong and Zhang, 2015) STAT5B sgRNA
sequence are as follows:
STAT5B-CRISPR1-SENSE: GCAATGTTAGCAGCAACACC
STAT5B-CRISPR1I-ANTISENSE: GGTGTTGCTGCTAACATTG
STAT5B-CRISPR2- SENSE: TGACCATTCCTTCCTTAGTC
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STAT5B-CRISPR2- ANTISENSE: GACTAAGGAAGGAATGGTCA
STAT5B-CRISPR3- SENSE: CTAAGAATTTTACGACAATA
STAT5B-CRISPR3- ANTISENSE: TATTGTCGTAAAATTCTTAG
STAT5B-CRISPR4- SENSE: AAGACTTCACACACATCTTG
STAT5B-CRISPR4- ANTISENSE: CAAGATGTGTGTGAAGTCTT
Mice
LMP1flSTOP mice on a BALB/c background, Ncr1-cre mouse strains on the C57BL/6
background were purchased from the Jackson Laboratory. Blimp1f/f mice on C57/b6
background were kindly given to us by Dr. Alexander Tarakhovsky, Cre reporter mice on
BALBc background by Dr. Kay-Uwe Wagner. To test Cre mediated recombination in
vivo, Ncr1-cre mice crossed with GFP stopf/f mice to generate Ncr1-cre, GFP stopf/- mice
and mice in first generation were used for experiment. Ncr1-cre mice were crossed with
Blimp1f/f or Blimp1f/- to generate Ncr1-cre, Blimpf/-mice in first generation. Ncr1-cre;
Blimpf/- mice were crossed with Blimp1f/f to generate Ncr1-cre; Blimpf/f mice.
LMP1flSTOP mice were crossed with Blimpf/f or Ncr1-cre,Blimpf/f for at least 5 generation
to generate Blimpf/f,LMP1flSTOP and Ncr1-cre,Blimpf/f,LMP1flSTOP mice.
Antibodies for flow cytometry
The following antibodies were purchased from BD Biosciences: NK-1.1 (PK136), CD3e
(145-2C11), CD4 (RM4-5), CD8a (53-6.7), CD45R/B220 (RA3-6B2), CD19 (1D3),TCRβ
(H57-597), CD27 (LG3A10), CD11b (M1/70), NKp46 (29A1.4), CD69(H1.2F3). For flow
cytometry, single-cell suspensions were prepared from PBMC, lymph nodes, spleen,
bone marrow followed by red blood cell lysis. Purified rat anti–mouse CD16/CD32
(2.4G2; BD Pharmingen) was added to avoid nonspecific binding. Stained samples were
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fixed with 0.5% paraformaldehyde 4 °C overnight. Stained samples were analyzed using
FACSCantoII and FACSDiva software Version 6.1.2 (BD Biosciences). Cell number
were counted using BD Accur C6 Cytometer (BD Biosciences)
NK-cell purification, expansion, and function
Single-cell suspensions were prepared from 3-4 spleens/genotype. NK cells were
isolated using negative seletion NK cell isolation kit (Miltenyi Biotec) as unwanted cells
were labeled with magnetic beads and attached to the magnetic column while untouched
NK cells were collected. NK cells were expanded for 6-12 days in RPMI 1640 medium
containing 10% fetal calf serum (FCS), β-2ME, L-glutamine, and penicillin/streptomycin
supplemented with rhIL2 1000U/mL The purity as assessed by flow cytometry was >
90%-95%. For in vitro proliferation assays, freshly purified NK cells or NK cells at day 6
were seeded in 24-well plates under IL2 or IL15. Cells were stained with 0.4% trypan
blue and counted using automated cell counter (Invitrogen).
NK-cell cytotoxicity was analyzed by flow cytometry. Briefly, target YAC-1 cells
were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen) in
37°C for 1 hour. 1 × 103 target cells/well was incubated expanded NK cells at day 10 at
the indicated E:T ratios for 4 hours at 37°C. Propidium iodide (Sigma-Aldrich) was added
to each well immediately before flow cytometry. The percentage of specific lysis was
determined as CFSE+PI+.
In vivo T cell depletion
For antibody-mediated T cell depletion, 40 ug anti-CD3 antibodies (145-2C11) were
injected intraperitoneally (i.p.) everyday for 5 days every other week. In another
experiment, 30mg/kg body weight Cyclosporin A (Selleckchem) were injected
intraperitoneally daily along with 200ug anti-CD3 antibodies every 3-4 days.
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In vivo PolyIC stimulation
For acute poly IC stimulation, mice were injected i.p. with 20ug poly IC (Invivogen),
blood were collected retro-obitally on day 1 and day 3. For chronic poly IC stimulation,
mice were injected i.p. with 200ug polyIC every other day for 4 weeks. Lymphocyte
profile was analysis in different organs.
Statistical analysis
Mean and SEM were calculated using Microsoft Office Excel (Microsoft), two-tailed
unpaired t-test was applied, p<0.05 was considered statistically significant.
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Figure 2-1:Total number of mutations identified by RNA-Seq in each NKTCL cases.
The number of missense, indel, nonsense and frameshift mutations are shown for 17
NKTCL cases as column percase based on the primary RNA-Seq pipeline.

38

A

B

C

D

39

Figure 2-2: The quality control of whole genome amplification procedure using NK
samples
(A) The reported PRDM1 mutation was detected by Sanger-PCR using whole genome
amplified (WGA) DNA from KAI3 cell line. (B) ~3kb DNA amplicon generated with PCR
using WGA DNA as a template from the KAI3 cell line. RPL13A specific primers were
used. (C)~3 kb fragment was generated using the WGA DNA from NKCL cases (n=3) as
in B. TAE-Agarose gel results of the PCR amplicons from three representative NKCL
cases were shown in duplicate. (D) 1ug of WGA genomic DNA from 4 representative
NKCL cases was run on 0.8% TAE-agarose gel to show the relatively large size of the
amplified genomic DNA.
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Figure 2-3: Generation of the mutated STAT3 or STAT5B expression construct
The STAT3 (A) and STAT5B (B) mutant expression construct generated and used in
functional studies are shown. The nucleotide changes and their corresponding effects on
the targeted residues are indicated. The altered nucleotides are shown in red color
inside the context of the amino acid codon affected. * NKYS cDNA, which has Y640F
mutation, was used as a template during cloning.
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Table 2-1: The STAT3/STAT5B mutations observed in γδ-PTCL, EATL, NKCL or
NKTCL cases and cell lines
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Table 2-2: Characteristics of NK and γδ- T cell lines used in the study and STAT3
mutation status
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Chapter III

Identification of mutations of JAK-STAT pathway genes in
natural killer and peripheral γδ T-cell lymphomas
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Introduction
Mature NK cell malignancies are classified under two major categories by the current
WHO classification(Jaffe, 2009): Aggressive NK cell leukemia (ANKL) and extra-nodal
NK/T cell lymphoma of nasal type (NKTCL). NKTCLs can be clinically classified as nasal
or extra-nasal lymphomas based on the primary site of the tumor (Au et al., 2009).
NKTCLs are rare malignancies with poor prognosis, particularly in advanced stage or
with extranasal presentation (Kwong, 2005). NKTCL shows marked geographic
differences in incidence with much higher frequency in East Asia and Central/South
America

(Au

et

al.,

2009).

NKTCLs

are

frequently

associated

with

EBV

infections(Kwong, 2005); however, the role of EBV in the pathogenesis of NKTCLs is not
well understood despite two studies suggesting an oncogenic role for EBNA1(Ian et al.,
2008) and LMP1(Komabayashi et al.) , genes encoded by EBV. Interestingly, nonhepatosplenic γδ -TCL (γδ-TCL NHS) showed a very similar gene expression profile to
NKTCL (Iqbal et al.) suggesting that these two diseases are highly similar and may use
the same oncogenic mechanisms during neoplastic transformation. There is little insight
into the aberrant pathways operative in γδ –TCLs.
Based on gene expression profile (GEP) differences between malignant and normal NK
cells (Huang et al., 2010, Iqbal et al., Ng et al.), constitutive activation of the JAK-STAT,
NF-kB, AKT and MYC pathways in NKTCL cases have been demonstrated. Given that
the activation of these pathways is a part of the normal NK cell activation process
(Dybkaer et al., 2007), it is possible that accumulation of oncogenic mutations in genes
affecting these pathways contributes to the neoplastic transformation of NK cells by
aberrantly promoting proliferation and survival.

However, there is still limited

information regarding the mechanistic basis for the constitutive activation of these
growth promoting pathways. Recently, two groups reported activating JAK3 mutations in
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NKTCL cases(Koo et al., Bouchekioua et al.) but a recent report showed that JAK3
mutations are not frequent in NKTCLs at least in Japan (Kimura et al., 2014).

This

marked difference in mutation frequency requires additional investigation.
The JAK-STAT pathway plays a key role in mediating cytokine signaling in NK cells
(Dybkaer et al., 2007). This role has recently been underscored by phosphorylation of
STAT1, STAT3 and STAT4 in mouse NK cells in response to MCMV infection (Bezman
et al., 2012). Constitutive activation of STAT3 and STAT5 is known to increase tumor
cell proliferation, survival and invasion(Yu et al., 2009). Aberrant STAT3 and STAT5B
activation has been shown in activated B-cell type diffuse large B-cell lymphomas (ABCDLBCL) (Lam et al., 2008) and CD8+ lymphoblastic lymphoma (Bessette et al., 2008),
respectively. Recently, activating mutations were identified in STAT3 (Jerez et al., 2012,
Koskela et al.) and STAT5B(Rajala et al.) in NK-large granular leukemia (LGL) and TLGL cases suggesting an oncogenic role for these mutations. These mutations were
located in the Src homology 2 (SH2) domain which is essential for homodimerization and
activation of STATs (O'Shea et al., 2002).
SOCS family proteins are induced in response to cytokine signaling and they have been
known to act as the negative regulators of the JAK-STAT pathway (Krebs and Hilton,
2001). Promoter methylation-mediated silencing of SOCS gene expression was shown
for SOCS1 in hepatocellular carcinoma (Yoshikawa et al., 2001) and multiple
myeloma(Galm et al., 2003) , for SOCS3 in lung cancer (He et al., 2003) and in
myeloproliferative disorders(Fourouclas et al., 2008) and for SOCS6 in gastric
cancer(Lai et al.). These studies showed that the JAK-STAT pathway may be
constitutively activated by hypermethylation-mediated silencing of the negative
regulators of the pathway in addition to activating mutations of the mediators of the
pathway.
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In this study, we investigated the genome-wide driver mutations in NKTCLs using a
combination of RNA sequencing, whole-exome sequencing (WES) and Sanger
sequencing, and identified activating mutations of STAT3 and STAT5B in the SH2
domain. STAT5B mutations were also observed at a high frequency in γδ-T-cell-derived
lymphomas (γδ-PTCLs). The mutatant proteins were more resistant to inactivation and
promoted cell growth and survival by binding to their direct targets. The JAK-STAT
activation could be partially inhibited by JAK1/2 inhibitors and expression of the negative
regulator SOCS6, suggesting a potential therapeutic option for these patients.
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Results
Frequent STAT3 and STAT5B mutations are identified by WTS in NKTCL cases
WTS was performed on resting NK cells, NK cells activated by IL2 or by K562-Clone9mb21, 17 NKTCL cases and 3 NK cell lines. Totally 9424 annotated SNVs were
identified in NKTCL cases and NK cell lines (Table 3-1). First, we validated the
mutations detected from our WTS data that may be functionally significant including the
mutations

in FAS, TP53, BRAF, MAP2K1, CREBBP, EP300 and MLL2 genes,

by

Sanger sequencing on the corresponding genomic DNA. The BRAF (G469A) and
MAP2K1 (K57N) SNVs have been detected frequently in epithelial tumors(Paik et al.,
2011, Marks et al., 2008, Shukla et al.) and have been shown to be oncogenic(Roring et
al., Wan et al., 2004, Marks et al., 2008). Of note, FAS and TP53mutations were
identified in NKTCLs by traditional Sanger sequencing in previous studies.
WTS identified a number of mutations that may affect the JAK/STAT pathway
including one STAT3 missense SNV (S614R, G618R and A702T) in each of three
NKTCL cases (3 of 17, 18%). Interestingly, all of the STAT3 SNVs were located in the
SH2 domain, a domain critical for STAT3 activation (Fig. 3-1A left). STAT3 S614R and
STAT3 G618R mutations were recently reported in NK-LGL or T-LGL leukemia cases
(Jerez et al., 2012). The third STAT3 mutation, STAT3 A702T was predicted to be
benign by Polyphen-2; however, this residue is located close to a phosphorylated
residue 705 raising the possibility that the mutation may alter the phosphorylation of
residue 705. STAT5B missense mutation (STAT5B N642H) was present in one of 17
(6%) NKTCL cases (Fig. 3-1B). STAT5A and STAT5B are highly conserved in this
residue and introduction of STAT5A N642H was reported previously to confer growth
factor independent growth in leukemic cell lines(Ariyoshi et al., 2000). In total, STAT3
and STAT5B mutations were observed in 4 of 17 (23.5%) NKTCL cases with WTS data.
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Targeted resequencing of STAT3 and STAT5B in NKTCL,γδ-PTCL and enteropathy
associated T-cell lymphoma (EATL) type II patient cohort and cell lines
NK cell and γδT cell share similar properties and functions, and our gene expression
profiling studies found that NKTCL and γδ-PTCL cases share a very similar profile with
each other and with normal NK cells. These observations suggest that NK cell and γδT
cell derived lymphoma may use similar oncogenic mechanisms. To compare the role of
STAT3/STAT5B SH2 domain mutations in NK cell and γδT cell derived lymphoma, we
screened the SH2 domains of STAT3 and STAT5B in additional NKCL and γδ-T cell
lines, as well as NKTCL, γδ-PTCL and enteropathy associated T-cell lymphoma (EATL)
type II patient cohort (Fig. 3-2A).
Since all observed SNVs were located in the SH2 domain, we sequenced the
SH2 domains of STAT3 and STAT5B by targeted Sanger sequencing in 35 additional
NKTCK cases collected in China (Fig. 3-3). One STAT3 D661Y mutation was observed
in 35 cases (2.9%) and two STAT5B mutations (Y665F and N642H) was observed in
two of these 35 screened cases (5.7%) (Fig. 3-2B, C). Frequency of both STAT3 and
STAT5B mutations was lower in Chinese NKTCL cases. These analyses yielded a
STAT3 and STAT5B mutation frequency of 5.9% in all NKTCL patients screened by
WTS, WES and/or Sanger sequencing (Fig. 3-2D, left).
RNA-Seq analysis on 3 NK-cell lines revealed an activating mutation, Y640F, in
the SH2 domain of STAT3 in NKYS cells, which was validated by Sanger sequencing
(Fig. 3-2B). Interestingly, 2 out of 3 additional NK-cell lines (SNK6 and YT) showed
STAT3 mutations when screened by Sanger sequencing, raising the STAT3 mutation
frequency to 50% of the 6 NK-cell lines studied (Fig. 3-2B). However, Sanger
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sequencing of the SH2 domain (exon14-exon18) of STAT5B in these NK-cell lines did
not reveal any STAT5B mutations.
Two recent studies reported the presence of JAK3 A572V, A573V or V722I
mutations in NKTCL (Koo et al., 2012, Jiang et al., 2015). However, neither WTS nor
hotspot sequencing of 40 NKTCL cases revealed these SNVs, consistent with a recent
report(Kimura et al., 2014). The discrepancy may be due to a variety of factors including
the genetic composition of the populations and different stimuli that initiate and sustain
the initial phase of NK-cell proliferation.
We also screened the SH2 domains of STAT3 and STAT5B in 3 γδ T-cell lines
and 24 γδ-PTCL cases [15 primary cutaneous (PC)-γδ-PTCL and 9 hepatosplenic (HS) γδ-PTCL cases]. Among the three γδ T-cell lines, we observed a STAT3 Y640F mutation
(SNT-15) and a STAT3 D661Y mutation (SNT-8), but no STAT5B mutation (Fig. 3-2B).
We identified only a STAT3 Y640F mutation in 1 of 24 γδ-PTCL cases (Fig. 3-2B). On
the other hand, 8 of 24 (33.3%) cases (4 PC and 4 HS) showed activating STAT5B
mutations in the SH2 domain (Fig. 3-2C, D).
Enteropathy associated T-cell lymphoma (EATL) is an aggressive PTCL with
higher incidence in Europe and USA (Delabie et al., 2011).

The disease is now

classified into two subtypes: Type I is the classical type expressing TCR-αβ and is
associated with celiac disease and gluten-sensitive enteropathy. EATL type II cases
have been shown to frequently express TCR-γδ ~ 78% in one study (Chan et al., 2011)),
and they are not associated with gluten-sensitive enteropathy. Targeted sequencing
revealed STAT5B N642H mutations in 7 of 19 EATL type II cases (36.8%) (Fig. 3-2C,
D). Intriguingly, all mutated EATL type II cases have γδ-T cell receptor expression (7/16
of TCR-γδ positive cases) underscoring the significance of STAT5B mutations in the
neoplastic transformation of γδ-T cells giving rise to different subtypes of γδ-PTCL.
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STAT3 is constitutively activated in NK cell lines with STAT3 mutations
To address whether STAT3 mutations activate the STAT3 pathway, we performed
western bloting on 6 NK cell lines using STAT3 and phospho-STAT3 antibodies.
Consistent with the targeted sequencing results, we observed high phospho-STAT3
expression in SNK6, NKYS and YT cell lines (Fig. 3-4). The three NK cell lines without
STAT3 mutations (NK92, KHYG1 and KAI3) express phospho-STAT3 at much lower
levels suggesting that STAT3 is highly activated in 3 of 6 (50%) of NK cell lines due to
the presence of activating mutations in the SH2 domain.

NK-cell lines with STAT3 mutations show high pY-STAT3 expression and shRNAmediated knock-down of STAT3 inhibits NK-cell line growth
Next, we transduced the NKYS and YT cell lines, which have the activating STAT3Y640F mutation, with empty vector or STAT3 shRNA with confirmed activity (Fig. 3-5) to
evaluate whether STAT3 silencing inhibits growth of NK cells. We quantified the
percentage of GFP positivity of STAT3 shRNA transduced cells at regular time intervals
starting 3 days post-transduction, and observed a markedly reduced percentage of
GFP+ cells compared to vector-only transduced cells, suggesting a strong negative
selection pressure after STAT3 knock-down (Fig. 3-6A-D). We did not observe a
decrease in the percentage of GFP+ population in STAT3 shRNA-transduced KAI3 cells,
which express wild-type STAT3 (Fig. 3-6E, F). STAT3 protein knockdown efficiency was
~72%, ~78% and ~39% in NKYS, KAI3 and YT cell lines, respectively (Fig. 3-6G, H),
which may account for the more moderate decrease in growth observed in YT cells after
STAT3 knock-down.
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Ectopic expression of STAT3 or STAT5B mutants promotes growth in KAI3 cells under
limiting IL2 concentrations.
Some of the STAT3/STAT5B mutations have been reported in other tumors and
are likely oncogenic, but other mutations have not been previously identified. We used
several approaches to confirm that these mutations are functionally significant and not
passenger mutations or uncommon SNPs. We performed site directed mutagenesis of
each of the mutants and transduced KAI3 cells, which lack STAT3 or STAT5B
mutations, with retroviruses expressing each of the STAT3 and STAT5B mutants and
determined the % of GFP+ cells post-transduction in regular time intervals. With only two
exceptions, all STAT5B- or STAT3-mutant transduced KAI3 cells showed significant
progressive positive selection under limiting IL2 concentrations compared with WTtransduced cells (Fig. 3-7A, B). STAT3 A702T mutant showed only modest positive
selection when compared with WT transduced cells.
Western blot analysis in cell lines clearly demonstrated an association of STAT3
mutations with increased phosphorylation. As there are no cell lines with STAT5B
mutations, we measured the phosphorylation of STAT5B proteins in STAT5B-mutant
transduced KAI3 cells and found it to be clearly increased compared with WT
transduced cells (Fig. 3-7C).

Ectopic expression of STAT5B I704L or N642H mutants promotes growth of primary
human NK cells
We transduced STAT5B mutants (N642H and I704L) into primary human NK cells
obtained through coculture with engineered K562 cells, K562-Cl9-mb21, and observed
robust promotion of cell growth in mutant compared to WT transduced cells (Fig. 3-8).
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Intriguingly, the effect of STAT5B N642H was prominent and the strongest among all
mutants tested in KAI3 cells or normal NK cells.

STAT5B target genes are transcriptionally upregulated in STAT5B-mutant transduced
cells through direct binding to conserved STAT5 binding sites
We evaluated the expression of known STAT5B targets, IL2Rα(Kanai et al., 2014), BCLXL(Silva et al., 1999), BCL2(Li et al., 2010), MIR155HG(Kopp et al., 2013) and
HIF2α(Fatrai et al., 2011) in KAI3 cells transduced with STAT5B mutants (N642H and
I704L) and observed significantly higher expression compared to WT or empty vector
transduced cells (Fig. 3-9A-E), indicating that the mutants are functionally active and
upregulate oncogenic STAT5B targets, which in part accounts for better promotion of
survival/growth in NK cells. Next, we performed ChIP-q-PCR on STAT5 binding sites for
these genes. Compared to KAI3 cells transduced with empty vector or wild- type
STAT5B, a robust increase in occupancy of STAT5 binding sites was observed in
STAT5B-N642H transduced KAI3 cells (Fig. 3-9F-J), indicating that increased STAT5B
binding due to the mutation, upregulates the expression of the target genes. Altogether,
these results suggest that the STAT3 and STAT5B mutations are oncogenic, driver
mutations.

Three-dimensional modeling and surface plasmon resonance (SPR) analysis of the
N642H mutant shows stronger affinity for the phosphorylated tyrosine Y699
STAT5B N642H is the most frequent mutation identified in γδ-PTCLs and appears to
have the highest functional potency. Hence, we sought to determine the molecular basis
of the functional alterations resulting from this mutation through structural analysis. To
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mimic homodimerization, we docked a tyrosine-phosphorylated STAT5B peptide into the
WT and mutant SH2 domains (Fig. 3-10A-C). Molecular docking showed that the peptide
has a significantly higher binding affinity to the N642H mutant than the WT (Fig. 3-10D)
largely due to the direct electrostatic interaction of the mutant histidine with the
phosphotyrosine. To confirm these modeling studies, we produced nonphosphorylated
wild-type and N642H STAT5B (residues 128 to 717), purified each to homogeneity, and
performed surface plasma resonance (SPR) studies. The wild-type and mutant STAT5B
proteins were coupled to individual channels of a CM5 SPR chip, and the
phosphopeptide KAVDG(p)YVKPQI was passed over each channel at increasing
concentrations (0.8 to 100 μM) in duplicates. The binding affinity of the peptide to the
wild-type and N642H mutant was determined by fitting the equilibrium saturation point as
a function of peptide concentration. The dissociation constants for the N642H mutant
and wild-type STAT5B were 2.9 μM and 14 μM, respectively (Fig.3-10E). While these
measurements represent a ~5 fold difference for the peptide to the monomeric STAT5BWT compared to N642H mutant, it is important to note that phosphoSTAT5B forms a
homodimer and thus there are two phosphotyrosine binding sites. Consequently, KDimer
= K Monomer1 • K Monomer2 which translates to a 25-fold increase in association constant for
the dimer. Hence, the homodimeric N642H mutant is substantially more stable than the
wild-type. This finding supports the molecular model and the in vitro cell based assay
observations.
To address whether the STAT5B-N642H mutation is associated with prolonged
STAT5B activation in the presence of acute JAK-STAT5 pathway activation, we
performed western blot analysis on IL2-activated YT cells in a time-course experiment to
evaluate P-STAT5 expression. The JAK-STAT5 pathway is known to be inducible in this
cell line (Nagy et al., 2009) and we observed P-STAT5 expression only in the presence
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of IL2 (data not shown). We incubated empty vector, STAT5B-WT or N642H-mutant
transduced YT cells with IL2 for 30 minutes, and evaluated P-STAT5 expression up to 6
h after IL2 withdrawal. P-STAT5 expression disappeared 1 h after transient IL2
stimulation in empty vector (EV) or STAT5B-WT transduced cells whereas it persisted
for more than 6 h in N642H-transduced cells (Fig.3-10F). These results suggest that the
N642H mutation increases affinity of the phospho-STAT5B dimer and thereby resulting
in far more persistent activation.

AZD1480 inhibits STAT3/STAT5B mutant transduced NK cells
Most NKCL and γδ-PTCL cell lines are still dependent on IL2 which signals mainly
through JAK1/2 to activate STAT3 and STAT5 (Johnston et al., 1996, Johnston et al.,
1995). JAK inhibitors are expected to be effective in interrupting this signaling pathway in
cells with wild-type STAT3 and STAT5. However, it is unclear whether the inhibitor
would effectively inhibit this pathway at a tolerable dosage in cells harboring the
mutants. We treated STAT3 or STAT5B-mutant and WT transduced KAI3 cells with 0.5
µM AZD1480, a selective JAK1/2 inhibitor(Derenzini et al., 2011). We quantified viable
cells at 72 h post-treatment and observed inhibition of growth in all the mutant STAT3
and STAT5B transduced cells (Fig. 3-11A, B). With higher concentrations of AZD1480,
we observed up to 60% inhibition in STAT5B N642H-mutant transduced cells (Fig. 311C, right), associated with reduced STAT5 phosphorylation in a dose-dependent
manner (Fig. 3-11D). Next, we treated YT and NKYS cells, which have STAT3
mutations, with the JAK1/2 inhibitor and observed dose-dependent inhibition of cell
growth (Fig.3-11E). These data suggest that JAK1/2 inhibitors may have therapeutic
efficacy for NKTCL and γδ-PTCL patients with the mutations. This may have immediate
clinical application as JAK1/2 inhibitors are already approved for myeloproliferative
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disorders (Pardanani, 2008, Sonbol et al., 2013). Thus they are available for trials in
NKTCL or γδ-PTCL patients while STAT3 and STAT5B inhibitors are still not clinically
available. Further development of small-molecule inhibitors targeting STAT3 or STAT5B
dimerization or DNA binding or siRNA approaches may synergize with JAK1/2 inhibitors
to improve the outcome in these diseases with currently dismal prognosis.

Activating STAT3 mutations coordinated with silencing of SOCS6 in NKTCLs
In our previous study we showed that SOCS6 was silenced through promoter
methylation in NKCL cases and NK cells lines. The SOCS6 mRNA was expressed at low
level in 5 out of 6 NK cell lines compared to resting or activated NK cells and intriguingly
all NK cell lines with activating STAT3 mutations had low SOCS6 expression based on
q-RT-PCR (Fig. 3-12). To address whether there is cooperation between activating
STAT3 mutations and silencing of SOCS6 in NKCL samples in establishing constitutive
activation of STAT3, we transduced the NKYS cell line which harbors a STAT3 Y640F
activating mutation with the empty vector or retrovirus expressing SOCS6 and quantified
the % of GFP+ cells in regular time intervals. The YT cell line is partially IL2 dependent
so IL2 was removed from cell culture medium 3 days post-transduction. We observed a
significant reduction of SOCS6 transduced YT cells when we compared the percentage
of GFP+ cells 4 days and 8 days post-transduction whereas no change was observed for
empty vector transduced

cells and similarly transduced control DHL16 cells, a

malignant B cell line that does not have STAT mutations (Fig. 3-13B). Next we tested the
effect of SOCS6 on apoptosis by staining the empty vector or SOCS6 transduced YT
cell line with early apoptotic marker Annexin V. We observed significantly higher % of
AnnexinV+/GFP+ cells in SOCS6 transduced YT cells compared with empty vector
transduced cells (4.5% vs 12.5% in empty vector or SOCS6 transduced cells,
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respectively)

(Figure 3-14A,B). To address whether SOCS6 mediated negative

selection pressure is due to inhibition of the JAK-STAT3 pathway, we performed western
blot analysis to evaluate P-STAT3 levels. P-STAT3 protein expression in SOCS6
transduced NKYS cells was lower compared with empty vector transduced cells (Fig 314C). These finding indicated that activating STAT3 mutations cooperated with silencing
of SOCS6 in NKCL samples, resulting in enhanced activation of STAT3.
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Discussion
Identification of possible oncogenic signaling pathways in malignant NK cells could give
us an insight on the mechanism of the pathogenesis of NKTCL as well as suggesting
potential therapeutic strategies. Previous GEP-based studies reported several aberrant
activated pathway in NKTCL such as the MYC, WNT, NF-B a nd TG Fb pa thwa ys(Iqbal
et al.). The constitutive activation of different pathways is often due to the accumulation
of multiple genomic imbalances or mutations that cause the activation of oncogenes or
inactivation of tumor suppressor genes. In our study, we investigated the genomic
abnormalities occurring in NKTCL and γδT derived lymphoma at different levels. At the
chromosomal level, we identified chromosomal copy number abnormalities such as
gain/loss by aCGH. We found 6q22 loss was the most frequent abnormality in NKTCL
samples. At the DNA level, we investigated epigenetic changes by analyzing global
methylation profile using the “methylation-sensitive cut counting” (MSCC) assay. We
identified 95 genes with strong evidence for being silenced though promoter methylation,
including BCL2L11 (BIM), PTPN6 (SHP1), TET2, SOCS6, and ASNS.In this study, we
investigated and compared the somatic mutation profile of NKTCL and other γδT derived
lymphomas using next generation sequencing (NGS). NGS study of NKTCL and γδT
should enable the identification of the full spectra of oncogenic mutations contributing to
the aberrant activation of oncogenic pathways or inactivating of JAK-STAT pathways
leading to the transformation of NK cells. This knowledge will aid in the development of
the targeted therapies with better efficacy and less cytotoxicity.
Although STAT3 or rarely STAT5B mutations have been reported in
malignancies such as B-cell lymphomas(Ohgami et al., 2014), angioimmunoblastic T-cell
lymphoma(Odejide et al., 2014) , CD30+ T-cell lymphoma(Ohgami et al., 2013) and the
indolent LGLL disease(Qiu and Fan, 2016), our study describes prevalent activating
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STAT5B and STAT3 mutations in aggressive lymphomas of NK and γδ-T cell of origin.
The frequency of activating STAT3 mutations was much higher in NK (50%) and γδ-Tcell lines (67%) compared with NKTCL (5.9%) or γδ-PTCL patient samples (8.3%). This
suggests that JAK-STAT3 pathway activation may be more critical in cell survival
independent of stromal components and that consequently the activating mutations are
selectively enriched in cell lines.
Intriguingly, STAT5B mutations were far more frequent in γδ T-cell lymphomas
including multiple subtypes: hepatosplenic, EATL type II and other mucocutaneous γδPTCL (34.9%) than in NKTCL cases (5.9%). It is worth mentioning that in the 2016
revision of the World Health Organization (WHO) classification of lymphoid neoplasms, EATL
type II s formally renamed as monomorphic epitheliotropic intestinal T-cell lymphoma
(MEITL) due to its distinctive features. Our study showed that the STAT5B mutations
were highly associated with γδMEITL. All these observations imply a pivotal role of
STAT5B in γδ-PTCL pathogenesis.
Two groups reported frequent activating JAK mutations in NKTCL. In our study
and other recent studies(Kimura et al., 2014), we failed to detect the JAK3 mutations in
NKCLs, an in some studies JAK3 mutations were observed in a low frequency. This
suggests that JAK3 mutations may not be frequent in NKTCLs, at least in the population
that we studied. This discrepancy may be due to a variety of factors including but not
limited to the characterization of malignant NK samples.
Importantly, our in vitro functional data suggested that mutant STAT3/STAT5B,
act as transcriptional activators, which contribute to the potent proliferative and survival
ability of NK cells under limited IL2 condition by directly binding and upregulating genes
involved in cell proliferation and cell cycle. Even though mutant STAT3/STAT5B had a
higher binding potency to their target, their activation still required the phosphorylation by
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upstream JAK kinase as withdrawal of IL2 result in a decrease in mutant pSTAT3/STAT5B level. However, mutant STAT3/STAT5B can form a tightly associated
dimer that is resistant to inactivation by phosphatases which results in a prolonged
activation of JAK-STAT pathway. Although the mutant p- STAT3/STAT5B dimers were
resistant to inactivation, the activation of JAK-STAT pathway still could be regulated
through upstream sites. Both JAK kinase inhibitor and ectopic expression of STAT
inhibitor SOCS disrupt the positive selection effect of mutant STATs. Therefore drugs
that target JAK-STAT pathway or reactivation of SOCS6 could be effective in treating
NKTCL or other γδ T cell derived lymphomas. Genomic-based strategies for cancer
therapy such as small interference RNA (siRNA) based therapy promise potent gene
inhibition with selectivity, even down to the level of single-nucleotide variant. Therefore,
mutant STATs-specific siRNA therapy may benefit NKTCL patients with particular
mutations, as this approach only target tumor cells results in less potential toxicity.
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Figure 3-1: Activating JAK-STAT pathway mutations are frequent in NKTCL cases.
The location of the mutated residues in the SH2 domain of STAT3 (A) and STAT5B (B)
and the type of residues mutated in other members of the JAK-STAT pathway genes (C)
in NK-cell lines and/or NKTCL cases are shown. The chromatograms show the relative
height of the sequencing peak for the mutations compared with the WT allele.
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Figure 3-2: Activating STAT3 and STAT5B mutations are frequent in lymphomas of
NK or γδ-T cell of origin.
(A) The diagram shows the type of mutation analyses performed and the number of
tumour samples used for each analysis. The locations of the primers used for PCR and
Sanger sequencing of the STAT3 andSTAT5B SH2 domains are shown in. The location
of the mutated nucleotides found in the SH2 domains of STAT3 (B) and STAT5B (C) in
tumour cases (NKTCL, γδ-PTCL (PC-γδ-PTCL and HS-γδ-PTCL) or EATL type II) and
cell lines (NK and γδ-T cell lines) are shown (not to scale). Mutations of different tumour
cases or cell lines are indicated with different symbols over the SH2 domains, and the
disease types to which these symbols refer are shown in the upper right corner of the
panels. Other than A702T, all STAT3 mutations were reported in LGLL by Koskela et al
and Jerez et al STAT5B N642H and Y665F mutations were rarely (~1%) observed in
LGLL by Rajala et al. (D) the percentages of STAT3 and STAT5B mutations in NKTCL
(n=51), γδ-PTCL (n=24) or EATL type II cases (n=19) are shown with pie charts. Apart
from the STAT5B Y665F mutation identified using WES; all SNVs identified in this study
have been cross-validated on genomic DNA with Sanger sequencing using both forward
and reverse primers. *: two NKTCL tumour samples with WTS data was re-classified
later as PC-γδ-PTCL due to γδ-TCR expression. One of these two reclassified cases is
the sample with the STAT3-G618R mutation.
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Figure 3-3: The locations and amplicon sizes of Sanger primers for the exons in
the SH2 domain of STAT3 and STAT5B.
(A) Primer pairs generating small size amplicons for STAT3 Sanger sequencing of FFPE
tumor samples are shown as arrows above the diagram. Primer pairs generating larger
size (>350 bp) amplicons used for samples with high molecular weight DNA are shown
with arrows below the diagram. The colors of the arrow correspond to different exons.
(B) The locations of the primer pairs used for Sanger sequencing of the STAT5B SH2
domain in FFPE tumor samples are shown as arrows above the diagram. The locations
of the primer pairs generating >500bp size amplicons used for Sanger sequencing
STAT5B SH2 domain in cyropreserved NKTCL or γδ-PTCL samples are shown as
arrows below the diagram.
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Figure 3-4: NK cell lines with STAT3 mutations show high STAT3 activation.
Western blot was performed on whole cell lysates (WCL) from 6 NK cell lines using
phospho tyrosine (Y705)-STAT3 and STAT3 antibodies. The germinal center B cell line,
DHL16, which does not have STAT3 activation was used as a negative control. αTubulin was used to ensure equal loading of the samples. The name of the cell lines
used is indicated on top of the gel image. The presence or absence of activating STAT3
mutations is shown with (+) or (-) signs, respectively. NA: Not available.
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Figure 3-5: STAT3 knock-down efficiency in 293T and NKYS cells
(A) STAT3 knock-down efficiency was evaluated with q-RT-PCR on STAT3 shRNA
transfected 293T cells. STAT3 mRNA levels in STAT3 shRNA transfected 293T cells
were normalized to STAT3 expression in untrasnfected cells and compared with empty
vector transfected cells 51 h after transfection. (B) Evaluation of the STAT3 knock-down
efficiency in NKYS cells transduced with empty vector or STAT3 shRNA. STAT3 shRNA
transduced NKYS cells were purified by FACS sorting 3 days post-transduction to enrich
GFP+ cells. STAT3 mRNA expression was determined using FACS sorted NKYS cells
transduced with empty vector or STAT3 shRNA. Unsorted NKYS cells were used to
normalize STAT3 expression.
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Figure 3-6: NK-cell lines with STAT3 mutations show high pY-STAT3 expression
and shRNA- mediated knock-down of STAT3 inhibits NK-cell line growth
(A) Representative flow cytometric plots showing the percentage of GFP+ cells 3 days
(day 0) and 12 days (day 9) post-transduction of NKYS cells with empty vector (EV) or
STAT3 shRNA after removing IL2 from the culture medium at day 0. (B) Quantification of
the percentage of GFP+ cells post-transduction of NKYS cells with empty vector or
STAT3 shRNA at regular time intervals. In one experiment, cells were cultured in the
presence of IL2 (5-7 ng/ml) until 3 days (day 0) post-transduction and then IL2 was
removed from the culture medium. In the second experiment, IL2 was always included
post-transduction of NKYS cells. Each data point is representative of two biological
replicates. (C) Representative FACS plots showing the percentage of GFP+ cells of YT
cell line transduced with empty vector or STAT3 shRNA 3 days (day 0) or 15 days (day
12) post-transduction. (D) Quantification of the percentage of GFP+ cells by FACS
between 3 and 15 days post-transduction with empty vector or STAT3 shRNA. For one
week before transduction, YT cells were cultured in the presence of IL2. Three days
post-transduction (day 0), cells were transferred to medium lacking IL2. (E)
Representative FACS plots showing the percentage of GFP+ cells in empty vector or
STAT3 shRNA transduced KAI3 cells. (F) Quantification of the percentage of GFP+ cells
after transduction of KAI3 cells with empty vector or STAT3 shRNA. 3 days posttransduction (day 0), the percentage of GFP+ cells was determined by flow cytometry,
and cells were switched to NK culture medium with reduced IL2 (25 IU/ml).
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Figure 3-7: Ectopic expression of STAT3 or STAT5B mutants promotes growth in
KAI3 cells under limiting IL2 concentrations.
(A) Quantification of the percentage of GFP+ cells post-transduction of KAI3 cells with
each STAT3 mutant observed in tumor samples. Transduced cells were cultured in
regular IL2 concentrations for 4 days, then switched to limiting (25 IU) IL2
concentrations. Day 0 = 4 days post-transduction. Each data point shows the mean of
biological replicates. The average values for the % of GFP+ cells at day 0 were 6.9%,
3.2%, 6.0%, 2.8%, 4.1%, 4.3% and 3.2% for EV, STAT3-WT, S614R, G618R, Y640F,
D661Y or A702T transduced cells, respectively. (B) Quantification of the percentage of
GFP+ cells post-transduction of KAI3 cells with each STAT5B mutant observed in tumor
samples as in A. Means ±SD of 2 independent experiments with replicates are shown
(n=4). The average values for the % of GFP+ cells at day 0 were 4.8% ,6.8% , 5.9%,
5.7%, 8.2%, 6.7% for EV, STAT5B-WT, E579K, N642H, Y665F or I704L-mutant
transduced cells, respectively.

The percentage of GFP+ cells for each sample is

normalized to day 0 in both A and B. (C) P-STAT5 (Y699) and STAT5 protein expression
levels in KAI3 cells transduced with STAT5B mutants are shown by western blot. Six
days post-transduction, the GFP+ population of STAT5B-mutant transduced cells was
isolated by FACS, and then placed into culture medium with limiting (25 IU/ml)
concentrations. Whole cell lysates were collected 11 days post-transduction. One
experiment representative of three experiments is shown.
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Figure 3-8: Ectopic expression of STAT5B I704L or N642H mutants promotes
growth of primary human NK cells
(A) Schematic representation of the coculture system used to activate and condition NKcells for retroviral transduction with N642H or I704L mutant forms of STAT5B. Pure NK
cells isolated from PBMCs were admixed with 100 Gr-irradiated engineered K562 cells,
K562-Cl9-mb21, as shown. Characterization of K562-Cl9-mb21 cells used to induce
proliferation of primary human NK cells was performed before(Somanchi et al., 2011).
The purity of NK cells (CD56+/CD3- cells) was ~94%. (B) Quantification of the
percentage of GFP+ cells post-transduction of primary NK cells with STAT5B-WT or each
of two STAT5B mutants (I704L or N642H) at three-day intervals. The percentage of
GFP+ cells for each sample is normalized to day 0. Day 0 indicates 5 days posttransduction. The average % of GFP+ cells at day 0 was 4.6%, 4.9% and 4.8% for
STAT5B-WT, N642H or I704L-transduced cells, respectively. Data are means ±SD of
biological replicates. Dead cells were stained with 0.5 µM of DAPI (Biolegend, cat.no:
422801) to exclude them from quantification.

83

A

B

D

E

F

I

C

G

H

J

84

Figure 3-9: STAT5B target genes are transcriptionally upregulated in STAT5Bmutant transduced cells through direct binding to conserved STAT5 binding sites
Relative mRNA expression of IL2Rα (A), BCL-XL (B), BCL2 (C), MIR155HG (D) and,
HIF2α (E) is shown in control vector or STAT5B-mut transduced cells prepared as
described in A. Means ± SD of two independent experiments (total combined samples =
4) are shown. * = p<0.01 and ** = p<0.05 compared to WT. ChIP-q-PCR results for
known STAT5 binding sites are shown for IL2Rα (F), BCL-XL (G), BCL2 (H), MIR155HG
(I) and HIF2α (J) in EV, STAT5B-WT or STAT5B-N642H transduced KAI3 cells. STAT5
pull-down normalized to IgG control as a fold difference compared with the STAT5B-WT
sample is shown in the y-axis using a log scale. STAT5B consensus sites and their
approximate distance to the TSS sites are indicated.
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Figure 3-10: Three-dimensional modeling and SPR analysis of the N642H mutant
shows stronger affinity for the phosphorylated tyrosine Y699
The phosphorylated STAT5B peptide involved in homodimerization was docked into the
SH2 domain of either WT (A) or N642H (B) STAT5B. The overlay of these structures (C)
shows little difference in the docking poses. In both cases, the N642 or H642 residue
was found to be in close proximity to the phosphorylated tyrosine on the STAT5B
peptide (D). The binding energy of these docked structures was calculated for both the
WT (-101.5 kj/mol) and N642H (-125.3 kj/mol). (E) SPR binding isotherms of
phosphopeptide with STAT5B WT (brown circles) and N642 mutant (blue triangles).
Calculated KD values of 14 µM and 2.9 µM for STAT5B WT and N642H mutant,
respectively, are indicated by vertical lines. An inset shows the Scatchard plot of the
same data (F) Western blot image showing P-STAT5(Y699) and STAT5 levels before or
after culturing empty vector (EV), STAT5B-WT or N642H mutant transduced, GFPsorted YT cells in the absence (no IL2) or the presence of IL2. YT cells were cultured in
the absence of IL2 in each stage of the experiment including one week before
transduction. The image is representative of two independent western blots.
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Figure 3-11: AZD1480 inhibits STAT3/STAT5B mutant transduced NK cells
25,000 STAT3-mutant (A) or STAT5B-mutant (B) transduced, GFP+-sorted KAI3 cells
were treated with 0.5 µM AZD1480 in 2ml medium for 72 h. Dead cells were stained with
trypan blue , viable cell number was determined using Vi-cell XR cell viability analyzer
(Beckman Coulter Inc.) and normalized to the corresponding untreated sample. Means
± SD of two biological replicates are shown. (C) Normalized viable cell number of
STAT5B-WT (left) or N642H mutant (right) transduced KAI3 cells treated with
progressively increasing doses of AZD1480 for 72 h. Each column represents mean ±
SD of three biological replicates. (D) P-STAT5 (Y699) levels were analyzed by western
blot on empty vector (EV), STAT5B-WT, N642H or I704L transduced KAI3 cells treated
with progressively increasing doses (0.5 µM,1 µM or 2 µM) of AZD1480 for 4h (E)
Normalized numbers of viable STAT3-mutated NKYS and YT cells treated as in (C) are
shown *: P<0.01 vs no treatment; **: p<0.05 vs no treatment. N.S.: Not significant.
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Figure 3-12: q-RT-PCR shows SOCS6 silencing in 5 of 6 NK cell lines.
R: Resting NK cells, A: 48h IL2 activated normal NK cells. The STAT3 mutation status is
indicated with a (+) or (-) sign for each NK cell line. A (+) sign indicates the presence of
the mutation.
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Figure 3-13: Ectopic expression of SOCS6 is associated with negative selection
pressure in NK cell lines with STAT3 mutations.
(A) Quantification of the % of GFP+ population in empty vector or SOCS6 transduced YT
cells at 2 day intervals for 4 days. Mean (+/- SD) was shown. Each data point represents
2-4 biological replicates. (B) Quantification of the % of GFP+ population in empty vector
or SOCS6 transduced DHL16 cells at 5 days and 7 days post transduction. Mean (+/SD) was shown. Each data point represents 2-4 biological replicates.

98

A

B

C

99

Figure 3-14: Ectopic expression of SOCS6 induces apoptosis in NK cell lines with
STAT3 mutations.
(A)A representative plot for AnnexinV-PE staining on GFP gated cells is shown for
empty vector or SOCS6 transduced YT cells 3 days post-transduction. (B) Quantification
of the % of AnnexinV+/GFP+ population in YT cells transduced with empty vector or
SOCS6 3 days post-transduction. Each data point represents a combination of biological
replicate with two technical replicates (n=4). *=p= 0.001. (C) NKYS cells were
transduced twice with empty vector or SOCS6 and GFP+ cells were sorted with FACS
two or four days post-transduction. Western blot was performed on GFP sorted vector or
SOCS6 transduced cells using P-STAT3 antibody. α-Tubulin was used as a loading
control to ensure equal loading.
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Chapter IV
Role of Blimp1 in NK cells homeostasis and function
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Introduction
Extranodal NK/T- cell lymphoma is an aggressive lymphoma with poor prognosis.
Studies revealed that this type of lymphoma is derived from cytotoxic lymphocytes of
both NK- and T-cell lineages. Nasal NK-cell lymphomas are either CD3-CD56+ or
CD3+(cytoplasmic),CD56+ and lack T cell receptor (TCR)γ and immunoglobulin heavy
chain gene (IgH) clonal rearrangement, whereas nasal T-cell lymphomas are either
sCD3+CD56+ or sCD3+CD56- with clonally rearranged TCRγ and germ-line IgH(Metgud
et al., 2011). Even though its molecular background has been investigated in the last
few years, the pathogenesis of NK/T cell lymphoma is still largely unknown. A distinctive
feature of this disease is the strong association with Epstein–Barr virus infection; EBV is
positive in 100% of NKCL cases by in situ hybridization for EBV-encoded small nonpolyadenylated RNAs (EBER) (Chiang et al., 1996). However, the role of EBV infection
in the pathogenesis of NKTCL is still not clear; the EBV-infected cells frequently express
latent membrane protein 1 (LMP1), which activate several downstream signaling
pathways such as NF-κB pathway that are likely involved in NK/T-cell activation and
proliferation(Chen, 2012). These LMP1-expressing proliferating cells are able to escape
from elimination by host cytotoxic T- lymphocytes (CTLs)(Young et al., 1989). Other
proteins that are expressed include Epstein–Barr virus nuclear antigen 1
(EBNA1) and latent membrane protein 2 (LMP2), and they may also be involved in
NKTCL (Ian et al., 2008, Fox et al., 2010).Genetic abnormalities leading to the activation
of oncogenes and inactivation of tumor suppressor genes likely play an important role in
NK/T cell malignant transformation.
In our previous studies, we found that PR domain zinc finger protein 1 (PRDM1)
was inactivated in NKTCL by the combination of chromosomal deletion and promoter
hypermethylation in 44% of NKTCL cases, and in vitro studies demonstrated that
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PRDM1 is a tumor suppressor gene in NKTCL(Kucuk et al., 2011).

The encoded

protein, PRDM1, also known as B lymphocyte-induced maturation protein 1(Blimp1), is
a transcriptional repressor that has various effects on the function and homeostasis of B
cells and T cells(Martins and Calame, 2008) and is frequently inactivated in B-cell
malignancies such as diffuse large B cell lymphoma (DLBCL)(Pasqualucci et al.,
2006).In B cells, Blimp-1 is expressed in plasmablasts and all plasma cells, and is a
master regulator of the differentiation of B cells into immunoglobubin secreting
cells(Savitsky and Calame, 2006).

Conditional knockout of Blimp1 using cre-loxp

system in the mouse resulted in the development of lymphoproliferative disorder
including DLBCL (Mandelbaum et al., 2010). In T cells, Blimp1 expression increases in
antigen-activated CD8+ and CD4+ T-cells and some CD25+ regulatory T-cells(Ozaki et
al., 2004, Kallies et al., 2006) , and is important for T cell homeostasis and effector
functions. Expression of Blimp1 was upregulated upon TCR stimulation. Blimp1-deficient
T cells proliferated more and produced excess IL2 and IFNγ. Mice lacking Blimp1 in
their T cells had more peripheral effector T cells and developed an inflammatory disease
(Ozaki et al., 2004, Kallies et al., 2006).
Unlike in T and B cells, Blimp1 is expressed in NK cells in all stages and
upregulated in mature or activated NK cell subsets. In our previous study, we observed
an increase in PRDM1 expression in activated NK cells, and knocking down PRDM1
resulted in a positive selection of NK cells. Whereas ectopic PRDM1 expression in
PRDM1-null NK cell lines resulted in G2/M cell cycle arrest, increased apoptosis, and a
strong negative selection. These finding, along with the observation that PRDM1 was
inactivated in NKTCL, indicated that PRDM1 is a potential tumor suppressor gene in
NKTCL. A recent study using chimeric mice reconstituted with Rag2−/−Blimp1gfp/gfp fetal
liver cells showed that Blimp1 is required for NK cell maturation and homeostasis
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(Kallies et al., 2011). Blimp1 was induced by IL15 in NK cells, and highly expressed in
the most mature NK cell subsets. The reconstituted chimeric mice had reduced NK cells
in peripheral and NK cell maturation was partially impaired in the transition from
CD27+KLRG1- to the CD27-KLRG1+ stage. However, due to lack of B cells and T cells,
this model cannot fully reflect the interaction of NK cells and other lymphocytes.
Therefore, we generated a NK-cell lineage conditional Blimp1 knockout mouse model to
study the effect of BLIMP1 in NK cell maturation and homeostasis, as well as the
possibility of development of NKTCL. In addition, we evaluated the phenotypic changes
in mice with NK-cell lineage-specific deletion of Blimp1 and coexpression of EBV
oncoprotein LMP1.

104
Results
Establish a NK-lineage specific Blimp1 knock out mouse model
Ncr1-cre mice previous generated by Dr. Alexander Tarakhovsky’s lab, which express
Cre recombinase under control of Ncr1 promoter, were crossed to Blimp1f/f mice,
previous generated in Dr.Veronika Sexl’s lab’ in which the exon encoding the DNA
binding domain was flanked by two loxP sites (“floxed”), resulted in Blimp1 knockout in
NK cells from the pro-NK cell stage (Fig. 4-1). The function and lineage specificity of
Ncr1-cre were tested by crossing Ncr1-cre mice with Cre reporter Cag-GFP

f/stop

mice,

previously generated in Dr. Kay-Uwe Wagner’s lab. The offspring express green
fluorescence protein upon Cre-mediated deletion of a loxP-flanked stop cassette. As
expected, Ncr1-dependent Cre-mediated GFP expression was restricted to the NK
compartment, as more than 90% of the GFP+ cells were NK cells (CD3-NK1.1+) in
blood and spleen (Fig. 4-2A). On average, 40% of the CD3-NKp46+ NK cells were GFP
positive in blood and spleen (Fig. 4-2B). No GFP expression was detected in T-lymphoid
cells, as analyzed by CD3, CD4, and CD8 staining, and B-lymphoid cells stained by
CD45R (B220) and CD19 (Fig. 4-2C).
To confirm Cre-mediated Blimp1 deletion in Blimp1f/f mouse NK cells, NK cells
were isolated from spleen using a negative selection NK cell isolation kit (Miltenyi
Biotec). Genomic DNA was extracted from both NK cells and the rest of the splenocytes.
Primers spanning the deleted region were used to amplify the genomic DNA. The band
indicating Cre-mediated recombination was only observed in Ncr1-cre, Blimp1f/f NK
cells, and a remaining floxed blimp1 band indicated incomplete deletion. To quantify the
Cre-mediated Blimp1 deletion in Ncr1-cre, Blimp1f/f NK cells, primers within the deleted
region were use for quantitive PCR on genomic DNA and revealed 90% deletion
efficiency, which was higher than the efficiency we detected in Cre-reporter mice (Fig. 4-
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3). Since GFP expression in NK cells does not affect NK cell function and homeostasis,
we speculated that the Blimp1 knockout in NK cell might have a positive selection on NK
cell function and homeostasis. However it might also due to the difference of
accessibility between different loxP sequences.

Blimp1 has an effect on NK cell homeostasis and maturation in vivo
Ncr1-cre, Blimp1f/f mice were born at the expected Mendelian ratio. Hematopoietic
organs displayed no gross abnormalities; weight and cellularity of spleens and cellularity
of the lymph nodes and bone marrow were unaltered in Ncr1-cre, Blimp1f/f mice
compared with Blimp1f/f littermate controls. Analysis of CD3−NK1.1 cells in the
peripheral blood and spleens revealed a reduction of the percentage of NK cells in the
total lymphocyte gate and their absolute number in Ncr1-cre, Blimp1f/f mice (Fig. 4-4A).
However, the NK cell frequency and number were unaltered in lymph nodes and were
higher in bone marrow in Ncr1-cre, Blimp1f/f mice (Fig. 4-4A). T lymphocytes were
analyzed by staining with CD3, CD4 and CD8 antibodies; B lymphocytes were stained
with CD45R (B220) antibody. The numbers of total CD3+ cells, CD4+ and CD8+ T
lymphocytes and CD45R+ B lymphocytes were largely unchanged in peripheral blood,
spleen, lymph node and bone marrow (Fig. 4-4B).
NK cell maturation is a multi-step process; the mature subsets are mainly
distributed in the peripheral lymphoid organs or tissues whereas the immature subsets
are largely contained in the primary lymphoid organ such as bone marrow. Since NK cell
frequency and number were decreased in peripheral blood and spleen and increased in
bone marrow, we next investigated whether lack of Blimp1 could affect NK cell
maturation. In mice, NK cells can be divided into immature and mature populations by
expression of CD11b. CD11b- NK cells compose most of the NK cell population in fetal
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mice. In the adult, CD11b- NK cells are found mostly in the bone marrow and primary
lymphoid sites such as lymph nodes. CD11b+ NK cells are mostly found in peripheral
sites such as peripheral blood mononuclear cells (PBMCs) and can also be found in
spleen. CD11b+ NK cells can be further divided into 2 populations by the expression of
CD27. NK cell differentiation follows the pathway CD27-CD11b- (referred as DN for
double negative), CD27+CD11b-, CD27+CD11b+ (referred as DP for double positive)
and CD27-CD11b+. Different subsets have different features; DN NK cells display an
immature phenotype and highest potential for proliferation; CD27+ CD11b− and DP NK
cells show the best ability to secrete cytokines, whereas CD27-CD11b+NK cells are the
most mature subset exhibiting highest cytotoxicity.
In adult mice, relatively immature NK subsets (DP and CD27+CD11b-) were
present in lymph nodes (50.18± 1.87 % in control mice, 59.42 ± 1.90 % in Ncr1cre,Blimp1f/f mice) and bone marrow (60.1±1.45% in control mice, 82.17 ± 1.60 % in
Ncr1-cre,Blimp1f/f mice), mature NK subsets (DP and CD27-CD11b+) were found to
predominate in spleen (76.80 ± 4.09 % in control mice, 60.82 ± 2.29 % in Ncr1cre,Blimp1f/f mice) and PBMC (77.60 ± 4.25 % in control mice, 57.73 ± 4.95 % in Ncr1cre,Blimp1f/f mice). The frequency of mature CD11b+ NK cell subsets was reduced in all
the lymphoid sites, with a significant decrease from 39.93 ± 1.43% to 17.83 ± 1.61% in
bone marrow in Ncr1-cre, Blimp1f/f mice (Fig. 4-5A). Further analysis of subsets
distribution by staining CD27 and CD11b revealed that CD27+CD11b- NK cells were
significantly increased in peripheral blood, lymph nodes and bone marrow and the most
mature CD27-CD11b+ subset was decreased in all the lymphoid sites in the Ncr1cre,Blimp1f/f mice compared to the control mice (Fig. 4-5B). These results indicated that
Blimp1 has an effect on NK cell maturation and homeostasis.
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Blimp1 has an effect on NK cell proliferation and survival
In our previous study, we identified Blimp1 as a tumor suppressor gene in NKTCL, as
Blimp1 was silenced by the combination of allelic deletion and promoter methylation, and
knockdown of Blimp1 in human primary NK cells resulted in enhanced proliferation and
decreased apoptosis in vitro. To determine the proliferative potential of NK cells in the
absence of Blimp1, freshly isolated splenic Ncr1-cre, Blimp1f/f and wild-type NK cells
were cultured in media containing IL-2. Live cells were counted under the microscope as
death cells were excluded by staining with trypan blue. In another experiment, NK cells
were expanded in IL2 for 4 days followed by culturing in media containing IL15. Blimp1deficient NK cells exhibited enhanced growth in vitro compared with wild-type controls
(Fig. 4-6A). Wild-type NK cells started expanding 5 days after in vitro culture whereas
Blimp1-deficient NK cells expansion started 3 days after culture. Blimp1-deficient NK
cells proliferated more rapidly than wild-type cells when cultured in IL15 after initial
stimulation in IL2 for 4 days (Fig. 4-6A, right panel).
To test the survivability of NK cells, Day 4 NK cells were cultured in media with or
without IL2 for 24 hours; early and late apotosis was analyzed by staining with early
apoptosis marker Annexin V and cell viability dye 7-AAD. Under normal IL2 condition,
Ncr1-cre, Blimp1f/f and wild-type NK cells had similar baseline apoptosis (Fig. 4-6B).
Withdrawal of IL2 for 24 hours resulted in significant cell death and cell apoptosis. Ncr1cre, Blimp1f/f NK cells survived better (63.30 ± 0. 42% Anexin V-7-AAD- cells) than wildtype NK cells (42.10 ± 3.81 % Anexin V-7-AAD- cells) (Fig. 4-6B). Even though Ncr1-cre,
Blimp1f/f NK cells had defective maturation in vivo, the in vitro experiment indicated that
IL2 stimulation might contribute to the more potent proliferation and survival ability of
Ncr1-cre, Blimp1f/f NK cells. In our previous study, we identified IL2Ra (CD25) as a
direct target of Blimp1 in human NK cells.IL2Ra is the high affinity subunit of IL2
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receptor, it promotes cell proliferation and survival upon upregulation.As expected,
IL2Ra was expressed at a low level in freshly isolated NK cells and upregulated upon
IL2 stimulation; the increase was more significant in Ncr1-cre, Blimp1f/f NK cells (Fig. 46C).
Since Ncr1-cre, Blimp1f/f NK cells grew faster when activated by IL2, we
speculate that activated Ncr1-cre, Blimp1f/f NK cells might proliferate better in the
mouse when stimulated in vivo. To test our hypothesis, Ncr1-cre, Blimp1f/f and control
mice were injected with polyinosinic-polycytidylic acid (poly I:C), a dsRNA analog that
induces antiviral activity in vivo by activating NK cells and CD8+ T cells, either one time
as acute polyIC stimulation, or every other day for 4 weeks as chronic polyIC stimulation.
Peripheral blood was collected 1 day and 3 days after polyIC injection during acute
stimulation, and the lymphocyte profile was evaluated by FACS. While NK cell frequency
in control mice showed little change, NK cell frequency in Ncr1-cre, Blimp1f/f mice
increased 4-fold and 5-fold at day 1 and day 3 post injections, respectively (Fig. 4-7A),
whereas T cells and B cells remained at the same level (Fig. 4-7B,C). NK cell subset
distribution was similar in peripheral blood of control and Ncr1-cre, Blimp1f/f mice after
acute polyIC stimulation, however compare to unstimulated mice, stimulated mice had
more CD27+CD11b- subsets (less than 20% in unstimulated mice of both genotypes,
45.9% in polyIC stimulated control mice and 55.2% in polyIC stimulated Ncr1-cre,
Blimp1f/f mice) (Fig. 4-7B). After 4 weeks of chronic polyIC stimulation, spleens of both
groups were slightly enlarged to the same extent. NK cell frequency and NK cell number
were increased both in control and Ncr1-cre, Blimp1f/f mice; the increase in Ncr1-cre,
Blimp1f/f mice was greater (1.47 fold in control mice, 2.5 folds in Ncr1-cre, Blimp1f/f
mice) (Fig. 4-8A, B). There were more activated NK cells stained as CD69+ in Ncr1-cre,
Blimp1f/f mice (Fig. 4-8C). Similar to acute polyIC stimulation, NK cell subsets were
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distributed with a similar pattern as the percentage of CD27+CD11b- NK cells were
significanted increased (less than 30% in unstimulated mice of both genotypes, 69.8% in
polyIC stimulated control mice and 75.8% in polyIC stimulated Ncr1-cre, Blimp1f/f mice)
(Fig. 4-8D). Both in vitro and in vivo studies showed that Ncr1-cre, Blimp1f/f NK cells had
better proliferation potential.

Blimp1 has an effect on NK cell cytotoxicity
Our previous study demonstrated that PRDM1 was upregulated upon IL2 stimulation
and suppressed the expression of IFN γ and TNFa by directly binding to specific regions
on their promoters. mRNA isolated from resting NK cells and day 8 NK cells cultured in
the presence of IL2 were analyzed by real-time quantitative RT-PCR. Consistent with
our finding in human NK cells, TNFα and TNFβ (Lta) were expressed at low level in the
resting NK cells and unregulated upon IL2 stimulation. Expression of TNFα was higher in
resting and IL2 stimulated Ncr1-cre, Blimp1f/f NK cells. TNFβ was expressed at a low
level in both resting Blimp1f/f NK cells and wild-type NK cells, whereas its expression
significantly increased in Blimp1f/f NK cells upon IL2 stimulation (Fig. 4-9A). Since TNFs
are associated with NK cell cytotoxicity, we further tested the cytotoxic properties of
Blimp1-deficient NK cells. NK cells isolated from spleen of control and Ncr1-cre,
Blimp1f/f mice were expanded in IL2-containing media for 8 days. NK cells were then
cocultured with CFSE-labeled YAC-1 target cells at different effector to target ratios for 4
hours; killed target cells were stained with cell viability dye 7-AAD and quantified by flow
cytometry as CFSE+7-AAD+ cells. Ncr1-cre, Blimp1f/f NK cells showed greater cytotoxic
activity than the wild-type NK cells (Fig. 4-8B), which was different from the results found
using human NK cells, where Blimp1 did not affect NK cell cytotoxicity.
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Establish a NK-lineage specific Lmp1 knock in Blimp1 knock out double transgenic
mouse model
Although Blimp1 has been identified as a tumor suppressor gene in NKTCL, we have not
observed the development of NKTCL in mice with Blimp1 knock out alone . As
tumorgenesis is a multifactorial process, it is worthwhile to combine genomic aberrations
that would likely cooperate with blimp1 deficiency. EBV infection is highly associated
with NKTCL lymphoma, Epstein-Barr virus latent membrane protein 1(Lmp1) is the
major oncoprotein in B-cell transformation and is expressed in NK lymphoma cells. It is a
six-span transmembrane protein belonging to the TNF family. It functions as an activator
of both the alternative and canonical NFκB pathways in B-cell transformation and may
play an important role in NK cell activation as well. Thus we proceeded to evaluate the
effect of simultaneously loss of tumor suppressor gene Blimp1 and expression of
oncogenic Lmp1 on NKTCL development.
Ncr1-cre, Blimp1f/f or Ncr1-cre, Blimpf/- mice were crossed to Lmp1stopf/- mice to
generate Ncr1-cre, Lmp1stopf/- and Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice. Ncr1-cre,
Blimp1f/f,

Lmp1stopf/-

mice

have

Lmp1

coding

sequence

inserted

into

the Gt(ROSA)26Sor locus, along with a loxP flanked stop fragment placed between the
promoter and LMP1 coding sequence. Expression of the Lmp1 gene is blocked by
the loxP-flanked STOP fragment, but upon Ncr1-dependent cre-mediated excision of the
stop cassette, Lmp1 is expressed in NK cells. As mentioned above Blimp1 is deleted
simultaneously (Fig. 4-10)
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NK cells were severely reduced in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice
Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice was born at the expected Mendelian ratio.
Hematopoietic organs displayed no gross abnormalities; weight and cellularity of spleens
and bone marrow were unaltered in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice compared with
Blimp1f/f, Lmp1stopf/- littermate controls, however the lymph nodes were smaller in Ncr1cre, Blimp1f/f, Lmp1stopf/-

mice. Analysis of CD3−NK1.1 cells in the different lymphoid

sites revealed severe reduction of NK cell percentage and number in all the sites. The
frequency of NK cells was most significantly decreased in peripheral blood, as a 16 fold
(3.60 ± 0.37 % to 0.22 ± 0.05 %) decrease of NK cell was observed in Ncr1-cre,
Blimp1f/f, Lmp1stopf/- mice compared to the control mice (Fig. 4-11A). A 10- fold decrease
in NK cell frequency was observed is lymph nodes and bone marrow as well, whereas a
6-fold decrease in NK cell frequency was observed in spleen (Fig. 4-11A, upper panel).
The decrease in NK cell number was consistent with the decrease in NK cell frequency
as NK cell number was most significantly reduced in peripheral blood followed by bone
marrow, lymph nodes and spleen (Fig. 4-11A, lower panel). The decrease of NK cell
frequency and number was also more significant in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice
than that in Ncr1-cre, Blimp1f/f mice which showed a defect in NK cell maturation. We
were not able to evaluate the absolute number of NK cells in lymph nodes due to the
small size of the lymph nodes in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice. The frequency of
total CD3+ cells and CD45R+ B lymphocytes were largely unchanged in peripheral
blood, spleen, lymph nodes and bone marrow (Fig. 4-11B).
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Lmp1 expression altered NK cell subsets distribution
As we showed in the previous study, Blimp1 knockout in NK cells resulted in defective
NK cell maturation, we next tested if Lmp1 could alter the NK cell subset distribution. NK
cells subsets were analyzed for expression of CD27 and CD11b. The fraction of NK cells
in relatively mature CD11b+ subsets was markedly decreased while the percentage of
the immature CD11b- subsets increased in all the lymphoid sites (Fig. 4-12A). Compare
to other lymphoid sites, spleen had a less signification NK cell reduction (2.23± 0.32 x105
/spleen in Blimp1f/f, Lmp1stopf/- mice, 0.8 ±

0.09 x105/spleen in Ncr1-cre, Blimp1f/f,

Lmp1stopf/- mice ) and was the largest NK cell pool in mice, 95% of NK cells were CD11bin Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice but only 35% of NK cells were CD11b- in control
Blimp1f/f, Lmp1stopf/- mice (Fig. 4-12A). In control mice, the percentage of CD11b+ NK
cell was higher in peripheral blood and spleen and lower in lymph nodes and bone
marrow. In Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice, CD11b+ NK cells were severely reduced
in all the lymphoid sites compare to control mice (4.52 folds decrease in blood, 5.44
folds decrease in lymph nodes, 4.97 folds decrease in bone marrow and 13 folds
decrease in spleen). When the subsets distribution was more specifically evaluated, the
percentage of DN NK cell subset increased in all secondary lymphoid sites but remained
the same in bone marrow. The increased fraction of CD11b- NK cells in bone marrow
was mostly due to the increase of the CD27+CD11b- subset (Fig. 4-12B).

The decrease in NK cells in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice was due to
Immunosurveillance
Lmp1 is an EBV encoded protein that may be strongly immunogenic. It is possible that
NK cells expressing Lmp1 were recognized by the immune system as virus infected cells
and subsequently destroyed by T-cells despite of their presence throughout
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hematopoiesis. This speculation was also supported by a study in B cell-specific Lmp1
mice showing that, T cells were activated by lmp1-expressing B cells, and these
activated CD8 T cells killed lmp1-expressing B cells. This indicated that Lmp1expressing NK cells were killed by activated T cells, and the CD11b- NK cell subsets
proliferate to compensate for the loss of NK cells. During NK cell maturation, NK
progenitor cells gain NK1.1 first immediately followed by NKp46. More than 99% CD3NK1.1+ NK cells are CD3-NKp46 cells (Walzer et al., 2007). Thus it is likely most of
these CD11b- NK cells still express Lmp1 but they are able to escape
immunosurviliance due to their potent proliferation ability.
In order to study the property of simultaneous Blimp1 knockout and lmp1
expressing NK cells without the interference of T cell-mediated cell killing. We depleted
T cells in Ncr1-cre, Blimp1f/f, Lmp1stopf/- and control mice by injecting blocking CD3
antibodies. The blocking monoclonal CD3 antibodies are known to cause cytokine storm
both in human and mice (Ferran et al., 1990). After anti-CD3 injection, mice loss body
weight immediately in the first week. Then body weight started increasing until returning
to normal in another week. NK cells and T cells in anti-CD3 injected mice were
monitored at week 2, 3 and 4. At week 2, T cell depletion in control mice was more
efficient as all three mice had less than 20% T cells, whereas only one Ncr1-cre,
Blimp1f/f, Lmp1stopf/- mouse had less than 20% T cells (Fig. 4-13A). The NK cell
percentage increased in both Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice and control mice, and
the increase was higher in the two Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice with better T cell
depletion (<30% in total lymphocytes) (Fig. 4-13A).
To exclude the interference of T cells, NK cell percentage and number were
analyzed only using mice with less than 30% T cells (3 mice in control group, 2 mice in
Ncr1-cre, Blimp1f/f, Lmp1stopf/- group). The NK cell number increased rapidly 2 weeks
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after anti-CD3 injection in Ncr1-cre, Blimp1f/f, Lmp1stopf/- , indicating a better proliferation
capacity of these NK cells(Fig. 4-13B). This was also supported by the observation that
the percentage of CD27+ CD11b- NK cell was higher in Ncr1-cre, Blimp1f/f, Lmp1stopf/mice than in control mice (Fig. 4-1C). However, after week 2, T cells increased
dramatically in two of the Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice even though T cell
depletion was still efficient in control mice (Fig. 4-13A). As T cells increased in Ncr1-cre,
Blimp1f/f, Lmp1stopf/- mice, NK cells dropped back to a low level (Fig. 4-13A). Two months
of anti-CD3 injections depleted most of the T cells in control mice in all the lymphoid
sites, but failed to persistently deplete T cells in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice (Fig.
4-14). This finding supported our hypothesis that, Lmp1 expressing NK cells could
stimulate T cells, and as Lmp1-specific CD8+ T cell expanded, LMP+ NK cells were
eliminated. Intriguingly, although NK cells in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice
remained at a low level in bone marrow , the percentage of NKT cells (CD3+, NK1.1+)
increased dramatically (from 0.001% to 12.9% in bone marrow, 0.0008% to 13.06% in
spleen) (Fig. 4-15). T cells upon stimulation, can acquire NK markers such as CD16,
NK1.1 and NKp46. If these CD3+NK1.1+ positive cells also express NKp46 (Ncr1), then
they may also express Lmp1, therefore further experiment are needed to address
whether these NKT cells express Lmp1.
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Discussion
In this study, we showed that Blimp1 plays an important role in NK cell homoeostasis
and functions. A previous study using Blimp1GFP/GFP, Rag2-/-γc-/- reconstituted chimeric
mice showed that Blimp1 is a important player in the transcription network controlling NK
cell maturation. However in their study, Blimp1 was deleted in all hematopoietic cells,
which is not the case in real NKTCL cases, where Blimp1 deletion is NK cell specific. In
addition, chimeric mice lack other lymphocytes such as T cells and B cells. NK cells
depend on cytokines from the microenvironment, IL2; a cytokine primarily secreted by
CD4+ T cells has long been used for NK cell culture in vitro, suggesting an interaction of
NK cells and other lymphocytes. Therefore chimeric mice cannot fully reflect the
interaction of NK cells and their microenvironment. Thus in our study, we established a
NK-lineage specific Blimp1 knockout mouse model.
NK cells are believed to develop from common lymphoid progenitors (CLP) in
bone marrow or other extramedullary sites such as lymph nodes and thymus (Kondo et
al., 2001)14,15. In mouse, CLP develop into NK progenitors (NKP) as they acquire IL2/IL15 receptor beta chain (CD122), identified as Lin-CD122+ cells(Di Santo, 2006). NKPs
then express functional receptors following the order NK1.1, CD94/NKG2A, NKp46,
Ly49 receptors, DX5, CD43 and Mac-1 (CD11b) (Kim et al., 2002), and become
functional mature. In our study, the cre-mediated Blimp deletion was under the control of
the Ncr1 (NKp46) promoter, thus Blimp1 was knocked out starting after the NKP stage.
Consistent to the finding in the chimeric mice study, NK cell maturation was disrupted in
Ncr1-cre, Blimp1f/f mice. Peripheral maturation of NK cells is known to be a 4-stage
process marked by the expression of CD27, a member of the TNF-receptor superfamily,
and CD11b, a protein subunit of integrin alpha-M beta-2 (αMβ2). NK cells were reduced
in peripheral lymphoid sites such as peripheral blood and spleen. In contrast, NK cells
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were increased in bone marrow. This was in agreement with the finding that Ncr1-cre,
Blimp1f/f NK cells were impaired in the transition from relatively immature CD11bsubsets to the mature CD11b+ subsets. CD11b, also known as macrophage-1
antigen (Mac-1), along with common integrin β2 subunit (CD18), forms the heterodimer
integrin αMβ2.
leukocytes,

Integrin αMβ2 is expressed on the surface of many innate immune

such

as

neutrophils,macrophages

and

NK

cells,

and

regulates

their adhesion and migration. Therefore, the lower number and frequency of NK cells in
peripheral sites might due to the impairment of NK cell migration.
Moreover, CD11b- NK cells consist of DN NK subsets and CD27+ CD11bsubsets. These two subsets are known to have greatest proliferative potential and
superior effector potential. This was supported by the finding that Ncr1-cre, Blimp1f/f NK
cells proliferated better in the presence of IL2 and IL15 in vitro and upon polyIC
stimulation in vivo. The better proliferation and survival of Ncr1-cre, Blimp1f/f NK cells
might be associated with the dysregulation of IL2Ra (CD25), a direct target of Blimp1 in
human NK cells. As we demonstrated, CD25 was transcribed at a detectable level in
resting NK cells. Upon stimulation with IL2, CD25 was upregulated in both Ncr1cre,Blimp1f/f NK cells and wild-type NK cells, however, the increase in Ncr1-cre,Blimp1
NK cells was about 2-fold higher. CD25 is the alpha chain of the IL-2 receptor and it can
associate with CD122 to form a high affinity IL2 receptor. CD25 is expressed in diffuse
large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), and high expression of
CD25 in the two types of lymphoma is correlated with a poor prognosis (Fujiwara et al.,
2014). Expression of high affinity IL2 receptor allows Ncr1-cre, Blimp1f/f NK cells to
survive in IL2 limiting conditions.
In contrast to the finding in experiments using chimeric mice, Ncr1-cre, Blimp1f/f
NK cells exhibited better cytotoxic function in vitro. This can be explained by the
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upregulation of Blimp1 targets involved in NK cell cytotoxicity such as TNFα and TNFβ,
as both genes were upregulated upon IL2 stimulation and a 5-fold increase in TNFβ was
observed in Ncr1-cre, Blimp1f/f NK cells compare to wild-type NK cells. Another
possibility is the formation of CD25+ cytokine induced memory-like (CIML) NK cells. It
has been show that brief preactivation with IL-12, IL15 and IL18 generated CIML NK
cells that expressed CD25 and later exhibit enhanced proliferation, cytokine secretion
and cytotoxicity via its high affinity αβγ IL2 receptor(Leong et al., 2014). Therefore,
deletion of Blimp1 might promote generation of CD25+ memory-like NK cells though IL2
alone.
Even though PRDM1 silencing is one of the major genetic alterations in NKTCL,
Blimp1 knockout alone was not sufficient to cause NKTCL in mice in steady state;
moreover, it impaired NK cell maturation. However, the accumulated Blimp1-knockout
NK cells exhibited potent proliferative and functional ability, which represent the highly
activated feature of malignant NK cells, in the presence of cytokine stimulation. Thus
the development of NKTCL may need another factor(s) that causes dysregulated NK cell
activation. Lmp1 is the major oncoprotein of EBV, which isdetected in 99% of NKTCL. It
activates the signaling pathways of nuclear factor-κB (NF-κB) and signal transducer and
activator of transcription (STAT), which is also activated upon IL2 stimulation. However,
the role of Lmp1 in NKTCL development was not studied as Lmp1-expressing Ncr1-cre,
Blimp1f/f NK cells were killed by immunesurveiliance. Prolonged anti-CD3 injection
resulted in a selection of Lmp1-specific cytotoxic T cells, as T cell depletion was
complete in control mice but got worse in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice. However
we observed a transient rapid growth of Lmp1-expressing Ncr1-cre, Blimp1f/f NK cells in
the first two weeks, when T cell depletion was optimal and Lmp1- specific T cells were
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not expanded. An alternative method needs to be applied to achieve a complete T cell
deletion in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice in future experimental studies.
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Figure 4-1: Strategy for breeding NK-lineage specific Blimp 1 knockout mice
Ncr1-cre mice were crossed with Blimp1f/f mice to generate heterozygous Ncr1-cre,
Blimp1f/- mice in thefirst generation. Ncr1-cre, Blimp1f/- mice were crossed with
Blimp1f/f mice to generate homozygous Ncr1-cre, Blimp1f/f mice.
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Figure 4-2: Ncr1-dependent Cre-mediated recombination was restricted to the NK
cell compartment
(A) Cre-mediated GFP expression as shown by flow cytometry in Ncr1-cre, Cag-GFP
report mice and littermate controls. Cells were analyzed within the lymphocyte gate (A)
Most GFP+ cells were showed expression of NK cell markers NKp46 and NK1.1,thus
most of the GFP+ cells were NK cells. (B) Percentage of GFP positive cells in NK cells
(CD3-NKp46+ ) in blood and spleen. (C-D) Absence of GFP expression in T and B cells
in different lymphoid sites. > 3 mice/genotype were used for analysis. LN, lymph nodes.
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Figure 4-3: Cre-mediated Blimp1knockout in mice
NK cells were isolated from the spleens of Ncr1-cre, Blimp1f/f and control mice (3
mice/phenotype) using a negative selection NK cell isolation kit. DNA was extracted from
isolated NK cells and attached remaining cells. (A) Blimp1 deletion was tested by PCR
using genomic DNA. A 200bp band indicates wild type Blimp1, a 250bp band indicates
floxed Blimp1, and a 400bp band indicates deleted Blimp1. The band indicating Blimp1
deletion was only detected in the Ncr1-cre, blimp1f/f NK cells. (B) Quantification of
Blimp1 deletion by q-PCR using genomic DNA.
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Figure 4-4: Blimp1 has an effect on NK cell homeostasis in vivo
Single cell suspensions were prepared from blood, spleen, lymph nodes and bone
marrow in one femur. The lymphocyte profile was analyzed by FACS. NK cells were
gated as CD3-NK1.1+, T cells were gated as CD3+ and different subsets were analyzed
by CD4 and CD8 staining, B cells were gated as CD3-CD45R+.(A) Upper panel
: absolute NK cell number in different lymphoid sites. Lower panel: percentage of NK
cells in total lymphocytes in different lymphoid sites. (B) Absolute number of B cells,
CD4+T cells and CD8+T cells in different lymphoid sites. LN: lymph node, BM: bone
marrow
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Figure 4-5: Blimp1 has an effect on NK cell maturation in vivo
NK cells were gated as CD3-NK1.1+. Different subsets were analyzed by the expression
of CD27 and CD11b. (A) Comparison of the percentage of CD11b- and CD11b+ NK
cells in different lymphoid sites in Ncr1-cre, Blimp1f/f mice and control mice. (B) NK cell
subset distribution in different lymphoid sites in Ncr1-cre, Blimp1f/f mice and control
mice.
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Figure 4-6: Blimp1 has an effect on NK cell proliferation and survival
(A)In vitro cultured NK cells were stained with 0.4% trypan blue and live cells were
counted using an automated cell counter (Invitrogen). Right panel: 105 freshly isolated
NK cells were seeded into a 24-well plate and cultured in medium containing 1000U/ml
IL2. Live cells were counted at the indicated time points. (B) NK cells were expanded in
media containing IL2 for 4 days; then 105 day4 NK cells were seeded into a 24-well plate
and cultured in the medium containing 1000U/ml IL15. Live cells were counted at the
indicated time points. (C) 105 day4 NK cells expanded in IL2 containing medium were
seeded into plate bottom 96-well plate with or without IL2 for 24 hours. Apoptotic cells
were stained with Annexin V and 7-AAD and analyzed by flow cytometry. (D) Expression
of known Blimp1 target IL2Ra was tested by q-RT-PCR in resting NK cells and IL2
activated NK cells.
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Figure 4-7: Acute PolyIC stimulation restores NK cells in peripheral blood
Mice were injected ip with 200µg polyIC. Peripheral blood samples were collected before
and 1 day and 3 days after injection. NK cell frequency in peripheral blood (A), NK cell
subset distribution (B) and B cell (C) and T cell (D) frequency in peripheral blood were
analyzed by FACS (4 mice/ genotype).
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Figure 4-8: Chronic PolyIC stimulation restores NK cells in spleen
4 mice/ phenotype were injected ip with 200µg poly IC every other day for 4 weeks.
Spleens were harvested and lymphocyte profiles were analyzed by FACS. (A)
Percentage of NK cells among total lymphocytes in spleen. (B) Absolute numbers of NK
cells in spleen within the lymphocyte gate. (C) Comparison of the percentage of
activated NK cells in Ncr1-cre, blimp1f/f and control mice. (D) Representative pattern of
NK cell subsets distribution in Ncr1-cre, blimp1f/f and control mice.
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Figure 4-9: Blimp1 has an effect on NK cell cytotoxicity
(A) RNA was extracted from freshly isolated NK cells and IL2 expanded NKcells at day
7. Expression of known Blimp1 targets TNFα and TNFβ was tested by q-RT-PCR. (B)
1000 CFSE labeled YAC-cells were cocultured with day 7 NK cells at the indicated
effector-target ratios in 200ul medium containing 1000U/ml IL2 in a round-bottom 96well plate for 4 hours at 37°C. Killed cells were labeled with PI and analyzed by flow
cytometry.
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Figure 4-10: NK-lineage specific Blimp 1 knockout and Lmp1 knockin mice
Blimp1f/f,Lmp1stopf/-

mice

have

Lmp1

coding

sequence

inserted

into

the Gt(ROSA)26Sor locus. The transcription of lmp1 was blocked by a loxP-flanked
STOP fragment placed between the ROSA26 promoter and the LMP1 coding
sequences. When bred with Ncr1-cre mice, the offspring had the STOP fragment
deleted in Cre expressing NK cells, resulting in expression of lmp1. At the same time,
Cre-mediated deletion of Blimp1 resulted in Blimp1 knock out in NK cells.
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Figure 4-11: NK cells were reduced in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice
Single cell suspensions were prepared from blood, spleen, lymph nodes and the bone
marrow in one femur. The lymphcyte profiles were analyzed by FACS. NK cells were
gated as CD3-NK1.1+. T cells were gated as CD3+ and different subsets were analyzed
by CD4 and CD8 staining. B cells were gated as CD3-CD45R+.(A) Upper panel:
absolute NK cell number in different lymphoid sites. Lower panel: percentage of NK cells
in total lymphocytes in different lymphoid sites. (B) Percentage of B cells (upper panel)
and T cells (lower panel) in different lymphoid sites. LN: lymph node, BM: bone marrow.
Absolute numbers of cells in lymph nodes could not be determined in Ncr1-cre,
Blimp1f/f, Lmp1stopf/- mice due to their small size.

147

A

148

B

149

Figure 4-12: NK cell subsets distribution in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice
NK cells were gated as CD3-NK1.1+. Different subsets were analyzed by the expression
of CD27 and CD11b. (A) Comparison of the percentage of CD11b- and CD11b+ NK
cells in different lymphoid sites in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice and control mice.
(B) NK cell subset distribution in different lymphoid sites in Ncr1-cre, Blimp1f/f, Lmp1stopf/mice and control mice.
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Figure 4-13: T cell depletion resulted in transient NK cell growth in Ncr1-cre,
Blimp1f/f, Lmp1stopf/- mice
Mice were injected iv with 5mg/kg anti-CD3 antibodies once a week. Peripheral blood
was collected retro-orbitally every week after the second week for 3 weeks. The
lymphocyte profile was evaluated by FACS. (B) NK cells were analyzed using mice with
optimal T cell depletion (< 30%). 3 mice in the control group, 2 mice in the Ncr1-cre,
Blimp1f/f, Lmp1stopf/- group were used. Percentage of NK cells in total lymphocytes
(Right panel) and absolute number of NK cells in peripheral blood are indicated as mean
± SEM. (C) Representative pattern of NK cell subsets distribution. NK cells were stained
with CD3-NK1.1+. Subsets were analyzed by the expression of CD27 and CD11b.
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Figure 4-14: T cell depletion in Ncr1-cre, Blimp1f/f, Lmp1stopf/- and control mice
Mice were injected ip with 40µg anti-CD3 antibodies daily for 5 consecutive days every
other week for 2 months. 4 surviving mice in each group were then euthanized and their
lymphocyte profile was evaluated in peripheral blood, spleen, lymph nodes and bone
marrow. T cells were stained with CD3. B cells were stained with CD45R. NK cells were
stained with CD3-NK1.1+. The percentage of T cells, B cells and NK cells is indicated for
each mouse.
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Figure 4-15: Occurrence of NKT cells in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice bone
marrow after two months T cell depletion
Mice were injected ip with 40µg anti-CD3 antibodies daily for 5 consecutive days every
other week for 2 months. 4 surviving mice in each group were then euthanized and their
lymphocyte profile was evaluated in peripheral blood, spleen, lymph nodes and bone
marrow. The frequency of NK cells (CD3-NK1.1+), NKT cells (CD3+NK1.1+) T cells
(CD3+) and B cells (CD3-CD45R+) is indicated as mean ± SEM.
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Chapter V
Summary and future directions
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Global gene expression, methylation and mutation profile studies enable us to gain a
better understanding of the changes in the comprehensive signaling network in NKTCL.
In this summary, I will describe our major findings including activating STAT3 and
STAT5B mutations and inactivation of Blimp1 in NKTCL.
Activating mutations in STAT3 and STAT5B were observed in lymphomas
derived from NK cells and γδ-T cells. STAT3 mutations mainly were present in NKTCL
cases and NK and γδ-T cell lines, whereas STAT5B mutations were frequently observed
in γδ-T cell-derived lymphomas including PC- and HS-PTCL and enteropathy associated
T-cell lymphoma (EATL) type II. All the mutations were present in the SH2 domain,
which is required for STAT protein dimerization. Our experiments clearly showed that the
mutated histidine within the SH2 domain of N642H STAT5B mutant bound to the
phosphotyrosine of another STAT5B with a 5-fold higher affinity, resulting in a more
stable N642H STAT5B homodimer or heterodimer that resistant to inactivation.
Moreover, the mutant p-STAT5B dimers bound to their targets with higher occupancy
and upregulated their expression. All of these resulted in the constitutive activation of the
JAK-STAT pathway, which promoted NK cell proliferation, survival and transformation in
NKTCL. The STAT3 and STAT5B proteins with activating mutations can still be
regulated by upstream molecules. In our study we showed that JAK inhibitor treatment
and SOCS6 overexpression can ablate the activating effect of mutant STAT3 and
STAT5B in NK cells. The role of activating STAT5B mutation in NKTCL is summarized in
Figure 5-1.
The question that arises after determining that mutant N642H STAT5B bound to
certain known targets such as IL2Ra, Bcl-2, Bcl-XL and MIR155, with higher occupancy
is whether the N642H STAT5B can bind to different targets. In the future, alterations in
target genes and the activity of signaling pathways will be identified by CHIP-SEQ and
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GEP analysis respectively. In order to distinguish the endogenous STAT5B and ectopic
wild-type or mutant STAT5B, NK cell lines will be transduced with vector containing
triple-flag tag labeled STAT5B. A triple-flag tag was fused to the C-terminus of WT or
mutant STAT5B, and the entire sequence was inserted into PMIG vector. We already
showed that fusion of triple-flag tag at its C-terminus did not affect STAT5B’s
phosphorylation and function. Western blot analysis showed that triple-flag wild-type and
N642H STAT5B were phosphorylated upon IL2 stimulation (Fig 5-2A). CHIP-q-PCR
using anti-flag antibody showed N642H STAT5B bound to its known target with higher
occupancy (Fig 5-2B).
To help identify the direct target genes of STAT 5B employing GEPanalysis, it is
important to capture the changes immediately after STAT5B activation, as prolonged
activation may result in secondary signaling changes. Thus, we established a regulated
STAT5B expression system for future application. In this system, triple-flag wild-type or
N642H STAT5B was fused to an engineered Escherichia coli dihydrofolate reductase
(DHFR) on its C-terminus, resulting in the rapid degradation of the entire fusion protein
until stabilized by the small molecule trimethoprim (TMP) (Fig 5-3). This allows us to
regulate the expression of STAT5B rapidly at the protein level.
As our in vitro experiments provided strong evidence to support our hypothesis
that activating STAT3 and STAT5B mutations were driver mutations leading to the
development of NKTCL, our next goal is to test our hypothesis in vivo. Conditional
STAT5B N642H knock-in can be achieved using the Cre-loxP system. Using the
CRISPR/Cas9 system, exon 16 of STAT5B will be replaced by a construct in which the
sequence of WT-STAT5B followed by the inverted sequence of STAT5B N642H is
flanked by two loxP sites with opposite orientation. We designed two sets of sgRNAs
targeting regions within intron 15 and intron 17 of the STAT5B gene. The sgRNAs
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should guide Cas9n nickase to the specific region and generate nicks on both DNA
strands, in this case, resulted in cutting out STAT5B exon 16 with its flanking sequences.
The double-strand break then can undergo homology-directed repair (HDR) in the
presence of the template containing homology arm and loxP sites flanking WT STAT5B
exon16- inverted STAT5B N642H exon 16 sequences, results in the replacement
STAT5B exon 16 with the loxP sites flanked WT STAT5B exon16- inverted STAT5B
N642H exon 16 sequence (Fig 5-4). The targeting donor vector WT STAT5B exon16inverted STAT5B N642H exon 16- Bluescript was generated using Gibson Assembly. In
its natural state, STAT5B encodes WT STAT5B, but when the STAT5B N642H f/- mice
were crossed with Cre mice, Cre mediated inversion of the WT STAT5B exon16 inverted STAT5B N642H exon 16 sequence results in the expression of STAT5B N642H
(Fig 5-5). SgRNAs were cloned into the PU57 vector for in vitro transcription using T7
promoter. SgRNAs, Cas9n protein and the targeting donor vector will be injected into
one-cell C57/Bl6 embryos. Pups with correct targeting will be identified by PCR and
Southern blotting. Knock-in mice will then be bred to Ncr1-cre mice to determine the
phenotypic effects of mutant STAT5B in NK cells and whether NKTCL develops.
In vivo study of Blimp1 showed that loss of Blimp1 immediately after the pro-NK
stage resulted in partial impairment of NK cell maturation. Compared to wild-type mice,
NK cell frequency in Blimp1-deficient mice was higher in bone marrow but lower in
peripheral blood, lymph nodes and spleen as the transition from immature CD11bsubsets to mature CD11b+ subsets was partially blocked. However, Blimp1-deficient NK
cells had better proliferation, survival and cytotoxic ability than wild-type NK cells in vitro
in medium containing IL2. Blimp1-deficient NK cells also proliferated better than wildtype NK cells upon stimulated with dsRNA analog polyIC in vivo. However, we did not
observe tumor develop in Ncr1-cre, Blimp1f/f mice. Since the development of NKTCL is
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a multifactorial process, additional genetic alternations are needed to establish a NKTCL
mouse model. Based on our recent finding, activating STAT3 and STAT5B mutations
are potential driver mutations in NKTCL. Given the observation that IL2 and IL15
activate STAT3 and STAT5B in NK cells, activating STAT3 and STAT5B mutations may
provide the stimulation signal to NK cells as it in IL2 and IL15 stimulation in vitro.
Therefore, we plan to cross Ncr1-cre, Blimp1f/f mice with STAT5B N642H knockin mice
to generate a NK-lineage specific Blimp1 knockout STAT5B N642H knockin mouse
model.
To study the role of EBV infection in NKTCL. We generated a NK-lineage specific
Blimp1 knockout Lmp1 knockin mouse model.

Lmp1-expressing NK cells were

destroyed by T cells in the mouse model. NK cells were restored within two weeks in
Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice after T cell depletion. However, after two weeks,
Lmp1-specific T cells started expending and destroyed Lmp1-expressing NK cells. In
order to test whether the combination Lmp1 expression and Blimp1 inactivation lead to
NKTCL development, we need to deplete T cells completely. Anti-CD3 blocking
antibodies are known to be associated with cytokine-storm related side effects.
Therefore,

increasing

anti-CD3

dose

is

not

practical.

Cyclosporin

A,

an

immunosupression drug that selectively inhibits T cell function at least in part by
suppressing transcription of NFAT target genes including IL2, can be used alone or with
CD3 antibody to enhance T cell depletion. Alternatively, Ncr1-cre, Blimp1f/f, Lmp1stopf/mice can be cross with TCRβ−/−;TCRδ−/− mice which lack T cells. To study the feature of
NK cell subsets, each NK subsets will be sorted and injected into Rag2−/−γc−/− mice
respectively. For in vitro functional study, NK cells will be isolated from Lmp1stopf/- and
Blimp1f/f, Lmp1stopf/- mice and treated with a soluble TAT-Cre to create Cre-mediated
deletion in vitro. As mentioned in the discussion section, a large portion of the remaining
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CD3+ cells were CD3+NK1.1+ NKT cells in Ncr1-cre, Blimp1f/f, Lmp1stopf/- mice. A study
showed that NKp46 is expressed on a minute fraction of NK-like T cells (Walzer et al.,
2007), and these NKp46-expressing NKT cells have higher proliferation and survival
ability and propensity to become leukemic in IL-15 transgenic mice (Yu et al., 2011). To
address the increase in NKT cells is due to the antigenic stimulation of Lmp1-expressing
NK cells or intrinsic oncogenic effect of Lmp1, it is important to determine whether these
CD3+NK1.1 NKT cells express NKp46, since Lmp1 expression is regulated by Cre
under the control of the NKp46 (Ncr1) promoter. NKp46 expression can be detected by
FACS. Lmp1 expression will be determined by q-RT-PCR on sorted CD3+NK1.1+ T
cells.
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Figure 5-1: Summary of the functional effects of activating STAT5B N642H
mutation
STAT5B N642H mutation was frequently observed in γδ-PTCL. Mutant STAT5B, upon
phosphorylation, can form a more stable dimer with prolonged activation. Mutant pSTAT5B bound to its target genes with increased occupancy and upregulated their
expression, resulting in increased cell proliferation and survival.
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Figure 5-2: Triple flag fusion does not alter STAT5B function
KAI3 cell were transduced with PMIG empty vector (EV) and vector containing wild-type
STAT5B-triple flag or STAT5B N642H-triple flag construct. Western blot analysis of total
STAT5 protein and STAT5B-triple flag fusion protein was performed using anti-STAT5
antibody and anti-flag antibody respectively. β-tubulin was used as loading control. (B)
ChIP-q-PCR results for known STAT5 binding sites are shown for IL2Rα, BCL-XL, and
BCL2 in EV, STAT5B-WT-triple flag or STAT5B-N642H-triple flag transduced KAI3 cells.
Anti-flag pull-down normalized to IgG control as a fold difference is shown in the y-axis
using a log scale. STAT5B consensus sites and their approximate distance to the TSS
sites are indicated.
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Figure 5-3: TMP-mediated dose-dependent expression of STAT5B using DHFR
vector
KAI3 cells were transduced with DHFR empty vector (EV) and vector containing wildtype STAT5B-triple flag or STAT5B N642H-triple flag construct. Cells were treated with
TMP at indicated concentrations for 12 hours. Western blot analysis of endogenous pSTAT5 protein and DHFR-STAT5B-triple flag fusion protein was performed using anti pSTAT5 antibody. The ~120kDa band indicates DHFR-STAT5B-triple flag fusion protein,
the ~90kDa bind indicates endogenous p-STAT5 protein.
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Figure 5-4: Schematics of the donor plasmid and targeting strategy for HDRmediated knock-in of loxP flanked WT STAT5B exon 16-inverted STAT5B N64H
exon 16 sequences.
Two sets of sgRNAs were designed to target a region in intron 15 and intron 16,
resulting in the deletion of the entire exon 16 and a portion of the flanking introns. The
donor template consists of upstream homology arm, two loxP sites with a spacer,
inverted human exon 16 with N642H mutation, mouse wild type exon 16, two loxP sites
and a downstream homology arm. The mouse STAT5B exon 16 will be replaced by the
construct after homology-directed repair.
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Figure 5-5: Schematic representation of conditional STAT5B N642H knockin by
Cre/loxP system.
The inverted mutant human exon 16 followed by mouse wild-type exon 16 was flanked
by two pairs of loxP sites. Without Cre recombinase, wild type mouse exon16 will be
transcripted. Two pairs of incompatible loxP sites were placed in head-to-head
orientation. Cre-mediated recombination between either pair of loxP sites lead to an
inversion resulted in transcription of mutant human exon 16. Another pair of loxP sites
positioned in the same direction leading to the deletion of loxP sites within the flanked
region so that the construct could no longer change.
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